Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Endoscopic examination, therapy or surgery of the luminal surface of the colon.
A benign epithelial tumor with a glandular organization.
Discrete tissue masses that protrude into the lumen of the COLON. These POLYPS are connected to the wall of the colon either by a stalk, pedunculus, or by a broad base.
Radiography using air, oxygen, or some other gas as a contrast medium.
A malignant epithelial tumor with a glandular organization.
The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL.
Tumors or cancer of the RECTUM.
Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI.
Tumors or cancer of the COLON.
The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.
Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A group of autosomal-dominant inherited diseases in which COLON CANCER arises in discrete adenomas. Unlike FAMILIAL POLYPOSIS COLI with hundreds of polyps, hereditary nonpolyposis colorectal neoplasms occur much later, in the fourth and fifth decades. HNPCC has been associated with germline mutations in mismatch repair (MMR) genes. It has been subdivided into Lynch syndrome I or site-specific colonic cancer, and LYNCH SYNDROME II which includes extracolonic cancer.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
A surgical specialty concerned with the diagnosis and treatment of disorders and abnormalities of the COLON; RECTUM; and ANAL CANAL.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tumors or cancer of the LIVER.
Neoplasms containing cyst-like formations or producing mucin or serum.
Endoscopic examination, therapy or surgery of the sigmoid flexure.
DNA present in neoplastic tissue.
Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the SKIN.
Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
Organic compounds which contain platinum as an integral part of the molecule.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Tumors or cancer of the LUNG.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Tumors or cancers of the KIDNEY.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
MutS homolog 2 protein is found throughout eukaryotes and is a homolog of the MUTS DNA MISMATCH-BINDING PROTEIN. It plays an essential role in meiotic RECOMBINATION and DNA REPAIR of mismatched NUCLEOTIDES.
Human colonic ADENOCARCINOMA cells that are able to express differentiation features characteristic of mature intestinal cells such as the GOBLET CELLS.
Excision of a portion of the colon or of the whole colon. (Dorland, 28th ed)
Tumor suppressor genes located in the 5q21 region on the long arm of human chromosome 5. The mutation of these genes is associated with familial adenomatous polyposis (ADENOMATOUS POLYPOSIS COLI) and GARDNER SYNDROME, as well as some sporadic colorectal cancers.
A cell line derived from cultured tumor cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the INTESTINES.
Human COLORECTAL CARCINOMA cell line.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE).
Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Tumors or cancer of the APPENDIX.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A raf kinase subclass found at high levels in neuronal tissue. The B-raf Kinases are MAP kinase kinase kinases that have specificity for MAP KINASE KINASE 1 and MAP KINASE KINASE 2.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Tumors or cancer of the PAROTID GLAND.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A DNA repair pathway involved in correction of errors introduced during DNA replication when an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. Excinucleases recognize the BASE PAIR MISMATCH and cause a segment of polynucleotide chain to be excised from the daughter strand, thereby removing the mismatched base. (from Oxford Dictionary of Biochemistry and Molecular Biology, 2001)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Biochemical identification of mutational changes in a nucleotide sequence.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Small, monomeric GTP-binding proteins encoded by ras genes (GENES, RAS). The protooncogene-derived protein, PROTO-ONCOGENE PROTEIN P21(RAS), plays a role in normal cellular growth, differentiation and development. The oncogene-derived protein (ONCOGENE PROTEIN P21(RAS)) can play a role in aberrant cellular regulation during neoplastic cell transformation (CELL TRANSFORMATION, NEOPLASTIC). This enzyme was formerly listed as EC 3.6.1.47.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
Tumors or cancer of the SIGMOID COLON.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE).
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the STOMACH.
Elements of limited time intervals, contributing to particular results or situations.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A negative regulator of beta-catenin signaling which is mutant in ADENOMATOUS POLYPOSIS COLI and GARDNER SYNDROME.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Tumors or cancer of the EYE.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
Tumors or cancer of the NOSE.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Antibodies produced by a single clone of cells.
Antimetabolites that are useful in cancer chemotherapy.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Excision of all or part of the liver. (Dorland, 28th ed)
A non-invasive imaging method that uses computed tomographic data combined with specialized imaging software to examine the colon.
Tumors or cancer of the SALIVARY GLANDS.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A broad category of carrier proteins that play a role in SIGNAL TRANSDUCTION. They generally contain several modular domains, each of which having its own binding activity, and act by forming complexes with other intracellular-signaling molecules. Signal-transducing adaptor proteins lack enzyme activity, however their activity can be modulated by other signal-transducing enzymes
Tumors or cancer of the human BREAST.
Tumors or cancer of the UTERUS.
Tumors or cancer of the PERITONEUM.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The presence of an uncomplimentary base in double-stranded DNA caused by spontaneous deamination of cytosine or adenine, mismatching during homologous recombination, or errors in DNA replication. Multiple, sequential base pair mismatches lead to formation of heteroduplex DNA; (NUCLEIC ACID HETERODUPLEXES).
Tumors or cancer of the DUODENUM.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A general term for various neoplastic diseases of the lymphoid tissue.

Transformation mediated by RhoA requires activity of ROCK kinases. (1/13490)

BACKGROUND: The Ras-related GTPase RhoA controls signalling processes required for cytoskeletal reorganisation, transcriptional regulation, and transformation. The ability of RhoA mutants to transform cells correlates not with transcription but with their ability to bind ROCK-I, an effector kinase involved in cytoskeletal reorganisation. We used a recently developed specific ROCK inhibitor, Y-27632, and ROCK truncation mutants to investigate the role of ROCK kinases in transcriptional activation and transformation. RESULTS: In NIH3T3 cells, Y-27632 did not prevent the activation of serum response factor, transcription of c-fos or cell cycle re-entry following serum stimulation. Repeated treatment of NIH3T3 cells with Y-27632, however, substantially disrupted their actin fibre network but did not affect their growth rate. Y-27632 blocked focus formation by RhoA and its guanine-nucleotide exchange factors Dbl and mNET1. It did not affect the growth rate of cells transformed by Dbl and mNET1, but restored normal growth control at confluence and prevented their growth in soft agar. Y-27632 also significantly inhibited focus formation by Ras, but had no effect on the establishment or maintenance of transformation by Src. Furthermore, it significantly inhibited anchorage-independent growth of two out of four colorectal tumour cell lines. Consistent with these data, a truncated ROCK derivative exhibited weak ability to cooperate with activated Raf in focus formation assays. CONCLUSIONS: ROCK signalling is required for both the establishment and maintenance of transformation by constitutive activation of RhoA, and contributes to the Ras-transformed phenotype. These observations provide a potential explanation for the requirement for Rho in Ras-mediated transformation. Moreover, the inhibition of ROCK kinases may be of therapeutic use.  (+info)

Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. (2/13490)

Bcl-2 is known to inhibit apoptosis and is thought to play a role in colorectal tumour development. Studies of the promoter region of bcl-2 have indicated the presence of a p53 responsive element which downregulates bcl-2 expression. Since p53 is commonly mutated in colorectal cancers, but rarely in those tumours showing microsatellite instability (MSI), the aim of this study was to examine the relationship of bcl-2 protein expression to MSI, as well as to other clinicopathological and molecular variables, in colorectal adenocarcinomas. Expression of bcl-2 was analysed by immunohistochemistry in 71 colorectal cancers which had been previously assigned to three classes depending upon their levels of MSI. MSI-high tumours demonstrated instability in three or more of six microsatellite markers tested, MSI-low tumours in one or two of six, and MSI-null in none of six. Bcl-2 expression in tumours was quantified independently by two pathologists and assigned to one of five categories, with respect to the number of cells which showed positive staining: 0, up to 5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, > or =76%. Bcl-2 negative tumours were defined as those with a score of 0. Bcl-2 protein expression was tested for association with clinicopathological stage, differentiation level, tumour site, age, sex, survival, evidence of p53 inactivation and MSI level. A significant association was found between bcl-2 expression and patient survival (P = 0.012, Gehan Wilcoxon test). Further, a significant reciprocal relationship was found between bcl-2 expression and the presence of MSI (P = 0.012, Wilcoxon rank sum test). We conclude that bcl-2 expressing colorectal cancers are more likely to be MSI-null, and to be associated with improved patient survival.  (+info)

99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. (3/13490)

Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid peptide with a wide range of biological activities. Recent reports suggest that VIP receptors are expressed on a variety of malignant tumor cells and that the receptor density is higher than for somatostatin. Our aims were to label VIP with 99mTc--a generator-produced, inexpensive radionuclide that possesses ideal characteristics for scintigraphic imaging--and to evaluate 99mTc-VIP for bioactivity and its ability to detect experimental tumors. METHODS: VIP28 was modified at the carboxy terminus by the addition of four amino acids that provided an N4 configuration for a strong chelation of 99mTc. To eliminate steric hindrance, 4-aminobutyric acid (Aba) was used as a spacer. VIP28 was labeled with 1251, which served as a control. Biological activity of the modified VIP28 agonist (TP3654) was examined in vitro using a cell-binding assay and an opossum internal anal sphincter (IAS) smooth muscle relaxivity assay. Tissue distribution studies were performed at 4 and 24 h after injection, and receptor-blocking assays were also performed in nude mice bearing human colorectal cancer LS174T. Blood clearance was examined in normal Sprague-Dawley rats. RESULTS: The yield of 99mTc-TP3654 was quantitative, and the yields of 125I-VIP and 1251-TP3654 were >90%. All in vitro data strongly suggested that the biological activity of 99mTc-TP3654 agonist was equivalent to that of VIP28. As the time after injection increased, radioactivity in all tissues decreased, except in the receptor-enriched tumor (P = 0.84) and in the lungs (P = 0.78). The tumor uptake (0.23 percentage injected dose per gram of tissue [%ID/g]) was several-fold higher than 125I-VIP (0.06 %ID/g) at 24 h after injection in the similar system. In mice treated with unlabeled VIP or TP3654, the uptake of 99mTc-TP3654 decreased in all VIP receptor-rich tissues except the kidneys. The blood clearance was biphasic; the alpha half-time was 5 min and the beta half-time was approximately 120 min. CONCLUSION: VIP28 was modified and successfully labeled with 99mTc. The results of all in vitro examinations indicated that the biological activity of TP3654 was equivalent to that of native VIP28 and tumor binding was receptor specific.  (+info)

Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. (4/13490)

Expression of CDX2, a caudal-related homeobox gene, was found to be decreased in colorectal carcinomas. Heterozygous null mutant mice as to Cdx2 develop multiple intestinal adenomatous polyps. To clarify the role of CDX2 in colorectal carcinogenesis, we determined its genomic structure, and searched for mutations of CDX2 in 49 sporadic colorectal carcinomas and ten hereditary non-polyposis colorectal cancers (HNPCC) without microsatellite instability. None of them exhibited a mutation. We further examined 19 HNPCC carcinomas with microsatellite instability for mutations in a (G)7 repeat site within CDX2. One of them (5.3%) exhibited one G insertion. Loss of heterozygosity was observed in 2 of the 20 (10%) informative sporadic carcinomas, and in one of the three (33.3%) informative HNPCC cancers. These data indicate that CDX2 may play only a minor role in colorectal carcinogenesis.  (+info)

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. (5/13490)

Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA level greater than 5 ng ml(-1), and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period, and 55 were eligible for cancer antigen analysis. Examination of the dose-effect relationships provides evidence for a causal relationship between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than with once daily dosing (11 out of 30, 37%) (P = 0.043, chi2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment compared with the screening period for patients receiving twice daily marimastat (P<0.0001), but not for patients receiving marimastat once daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies. Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.  (+info)

Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. (6/13490)

The conflicting results about the prognostic impact of tumour cell proliferation in colorectal cancer might be explained by the heterogeneity observed within these tumours. We have investigated whether a systematic spatial heterogeneity exists between different compartments, and whether the presence of such a systematic heterogeneity has any impact on survival. Fifty-six Dukes' stage B colorectal cancers were carefully morphometrically quantified with respect to the immunohistochemical expression of the proliferative marker Ki-67 at both the luminal border and the invasive margin. The proliferative activity was significantly higher at the luminal border compared with the invasive margin (P<0.001), although the two compartments were also significantly correlated with each other. Tumours with low proliferation at the invasive margin had a significantly poorer prognosis both in univariate (P = 0.014) and in multivariate survival analyses (P = 0.042). We conclude that Dukes' B colorectal cancers exhibit a systematic spatial heterogeneity with respect to proliferation, and tumours with low proliferation at the invasive margin had a poor prognosis. The present data independently confirm recent results from the authors, and provide new insights into the understanding of tumour cell proliferation in colorectal cancer.  (+info)

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. (7/13490)

Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency.  (+info)

Faecal occult blood screening and reduction of colorectal cancer mortality: a case-control study. (8/13490)

To estimate the efficacy of screening on colorectal cancer mortality, a population-based case-control study was conducted in well-defined areas of Burgundy (France). Screening by faecal occult blood test prior to diagnosis in cases born between 1914 and 1943 and who died of colorectal cancer diagnosed in 1988-94 was compared with screening in controls matched with the case for age, sex and place of residence. Cases were less likely to have been screened than controls, with an odds ratio (OR) of 0.67 [95% confidence interval (CI) 0.48-0.94]. The negative overall association did not differ by gender or by anatomical location. The odds ratio of death from colorectal cancer was 0.64 (95% CI 0.46-0.91) for those screened within 3 years of case diagnosis compared with those not screened. It was 1.14 (95% CI 0.50-2.63) for those screened more than 3 years before case diagnosis. There was a negative association between the risk of death from colorectal cancer and the number of participations in the screening campaigns. The inverse association between screening for faecal occult blood and fatal colorectal cancer suggests that screening can reduce colorectal cancer mortality. This report further supports recommendations for population-based mass screening with faecal occult blood test.  (+info)

Colorectal neoplasms refer to abnormal growths in the colon or rectum, which can be benign or malignant. These growths can arise from the inner lining (mucosa) of the colon or rectum and can take various forms such as polyps, adenomas, or carcinomas.

Benign neoplasms, such as hyperplastic polyps and inflammatory polyps, are not cancerous but may need to be removed to prevent the development of malignant tumors. Adenomas, on the other hand, are precancerous lesions that can develop into colorectal cancer if left untreated.

Colorectal cancer is a malignant neoplasm that arises from the uncontrolled growth and division of cells in the colon or rectum. It is one of the most common types of cancer worldwide and can spread to other parts of the body through the bloodstream or lymphatic system.

Regular screening for colorectal neoplasms is recommended for individuals over the age of 50, as early detection and removal of precancerous lesions can significantly reduce the risk of developing colorectal cancer.

A colonoscopy is a medical procedure used to examine the large intestine, also known as the colon and rectum. It is performed using a flexible tube with a tiny camera on the end, called a colonoscope, which is inserted into the rectum and gently guided through the entire length of the colon.

The procedure allows doctors to visually inspect the lining of the colon for any abnormalities such as polyps, ulcers, inflammation, or cancer. If any polyps are found during the procedure, they can be removed immediately using special tools passed through the colonoscope. Colonoscopy is an important tool in the prevention and early detection of colorectal cancer, which is one of the leading causes of cancer-related deaths worldwide.

Patients are usually given a sedative to help them relax during the procedure, which is typically performed on an outpatient basis in a hospital or clinic setting. The entire procedure usually takes about 30-60 minutes to complete, although patients should plan to spend several hours at the medical facility for preparation and recovery.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

Colonic polyps are abnormal growths that protrude from the inner wall of the colon (large intestine). They can vary in size, shape, and number. Most colonic polyps are benign, meaning they are not cancerous. However, some types of polyps, such as adenomas, have a higher risk of becoming cancerous over time if left untreated.

Colonic polyps often do not cause any symptoms, especially if they are small. Larger polyps may lead to symptoms like rectal bleeding, changes in bowel habits, abdominal pain, or iron deficiency anemia. The exact cause of colonic polyps is not known, but factors such as age, family history, and certain medical conditions (like inflammatory bowel disease) can increase the risk of developing them.

Regular screening exams, such as colonoscopies, are recommended for individuals over the age of 50 to detect and remove polyps before they become cancerous. If you have a family history of colonic polyps or colorectal cancer, your doctor may recommend earlier or more frequent screenings.

I'm sorry for any confusion, but "Pneumoradiography" is not a recognized term in the field of medicine or radiology. It seems that there might be a mix-up with the terminologies.

However, you may be referring to "Pneumonic Radiography," which means a chest X-ray used to diagnose pneumonia. Pneumonia is an infection or inflammation of the lung tissue, and a chest X-ray can help identify areas of increased density in the lungs that could indicate the presence of pneumonia.

If you meant something else, please provide more context or clarify your question, and I would be happy to help further.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

The rectum is the lower end of the digestive tract, located between the sigmoid colon and the anus. It serves as a storage area for feces before they are eliminated from the body. The rectum is about 12 cm long in adults and is surrounded by layers of muscle that help control defecation. The mucous membrane lining the rectum allows for the detection of stool, which triggers the reflex to have a bowel movement.

Rectal neoplasms refer to abnormal growths in the tissues of the rectum, which can be benign or malignant. They are characterized by uncontrolled cell division and can invade nearby tissues or spread to other parts of the body (metastasis). The most common type of rectal neoplasm is rectal cancer, which often begins as a small polyp or growth in the lining of the rectum. Other types of rectal neoplasms include adenomas, carcinoids, and gastrointestinal stromal tumors (GISTs). Regular screenings are recommended for early detection and treatment of rectal neoplasms.

The intestinal mucosa is the innermost layer of the intestines, which comes into direct contact with digested food and microbes. It is a specialized epithelial tissue that plays crucial roles in nutrient absorption, barrier function, and immune defense. The intestinal mucosa is composed of several cell types, including absorptive enterocytes, mucus-secreting goblet cells, hormone-producing enteroendocrine cells, and immune cells such as lymphocytes and macrophages.

The surface of the intestinal mucosa is covered by a single layer of epithelial cells, which are joined together by tight junctions to form a protective barrier against harmful substances and microorganisms. This barrier also allows for the selective absorption of nutrients into the bloodstream. The intestinal mucosa also contains numerous lymphoid follicles, known as Peyer's patches, which are involved in immune surveillance and defense against pathogens.

In addition to its role in absorption and immunity, the intestinal mucosa is also capable of producing hormones that regulate digestion and metabolism. Dysfunction of the intestinal mucosa can lead to various gastrointestinal disorders, such as inflammatory bowel disease, celiac disease, and food allergies.

Colonic neoplasms refer to abnormal growths in the large intestine, also known as the colon. These growths can be benign (non-cancerous) or malignant (cancerous). The two most common types of colonic neoplasms are adenomas and carcinomas.

Adenomas are benign tumors that can develop into cancer over time if left untreated. They are often found during routine colonoscopies and can be removed during the procedure.

Carcinomas, on the other hand, are malignant tumors that invade surrounding tissues and can spread to other parts of the body. Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and colonic neoplasms are a significant risk factor for developing this type of cancer.

Regular screenings for colonic neoplasms are recommended for individuals over the age of 50 or those with a family history of colorectal cancer or other risk factors. Early detection and removal of colonic neoplasms can significantly reduce the risk of developing colorectal cancer.

The colon, also known as the large intestine, is a part of the digestive system in humans and other vertebrates. It is an organ that eliminates waste from the body and is located between the small intestine and the rectum. The main function of the colon is to absorb water and electrolytes from digested food, forming and storing feces until they are eliminated through the anus.

The colon is divided into several regions, including the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum, and anus. The walls of the colon contain a layer of muscle that helps to move waste material through the organ by a process called peristalsis.

The inner surface of the colon is lined with mucous membrane, which secretes mucus to lubricate the passage of feces. The colon also contains a large population of bacteria, known as the gut microbiota, which play an important role in digestion and immunity.

Early detection of cancer refers to the identification of malignant cells or tumors in their initial stages, before they have had a chance to grow and spread. This is typically achieved through various screening methods and tests that are designed to detect specific types of cancers. The goal of early detection is to increase the chances of successful treatment and improve the overall prognosis for patients.

Some common methods used for early cancer detection include:

1. Regular screenings such as mammograms, colonoscopies, and Pap tests, which can help identify precancerous or cancerous cells in their earliest stages.
2. Imaging tests like CT scans, MRIs, and PET scans, which can help detect tumors that may not be visible through other screening methods.
3. Blood tests that look for specific biomarkers or tumor markers, which can indicate the presence of cancer in the body.
4. Genetic testing to identify individuals who may be at higher risk of developing certain types of cancer due to inherited genetic mutations.

It's important to note that while early detection is an important tool in the fight against cancer, it is not a guarantee of successful treatment or cure. However, it can significantly improve the odds of successful treatment and increase the chances of survival for many patients.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Hereditary Nonpolyposis Colorectal Neoplasms (HNPCC), also known as Lynch Syndrome, is a genetic disorder that significantly increases the risk of developing colorectal cancer and other types of cancer. It is characterized by the mutation in genes responsible for repairing mistakes in the DNA replication process, specifically the mismatch repair genes (MMR).

HNPCC is typically inherited in an autosomal dominant manner, meaning that a person has a 50% chance of inheriting the mutated gene from an affected parent. The syndrome is associated with the development of colorectal cancer at a younger age, usually before 50 years old, and often in the proximal colon. Individuals with HNPCC also have an increased risk for other cancers, including endometrial, stomach, small intestine, ovary, kidney, brain, and skin (sebaceous gland tumors).

Regular surveillance and screening are crucial for early detection and management of colorectal neoplasms in individuals with HNPCC. This typically includes colonoscopies starting at a younger age and performed more frequently than in the general population. Genetic counseling and testing may also be recommended for family members who may have inherited the mutated gene.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Sensitivity and specificity are statistical measures used to describe the performance of a diagnostic test or screening tool in identifying true positive and true negative results.

* Sensitivity refers to the proportion of people who have a particular condition (true positives) who are correctly identified by the test. It is also known as the "true positive rate" or "recall." A highly sensitive test will identify most or all of the people with the condition, but may also produce more false positives.
* Specificity refers to the proportion of people who do not have a particular condition (true negatives) who are correctly identified by the test. It is also known as the "true negative rate." A highly specific test will identify most or all of the people without the condition, but may also produce more false negatives.

In medical testing, both sensitivity and specificity are important considerations when evaluating a diagnostic test. High sensitivity is desirable for screening tests that aim to identify as many cases of a condition as possible, while high specificity is desirable for confirmatory tests that aim to rule out the condition in people who do not have it.

It's worth noting that sensitivity and specificity are often influenced by factors such as the prevalence of the condition in the population being tested, the threshold used to define a positive result, and the reliability and validity of the test itself. Therefore, it's important to consider these factors when interpreting the results of a diagnostic test.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

I'm sorry for any confusion, but "pilot projects" is not a medical term per se. Instead, it is a general term used in various fields, including healthcare and medicine, to describe a small-scale initiative that is implemented on a temporary basis to evaluate its feasibility, effectiveness, or impact before deciding whether to expand or continue it.

In the context of healthcare, pilot projects might involve testing new treatment protocols, implementing innovative care models, or introducing technology solutions in a limited setting to assess their potential benefits and drawbacks. The results of these projects can help inform decisions about broader implementation and provide valuable insights for improving the quality and efficiency of healthcare services.

Colorectal surgery is a medical specialty that deals with the diagnosis and treatment of disorders affecting the colon, rectum, and anus. This can include conditions such as colorectal cancer, inflammatory bowel disease (such as Crohn's disease or ulcerative colitis), diverticulitis, and anal fistulas or fissures.

The surgical procedures performed by colorectal surgeons may involve minimally invasive techniques, such as laparoscopic or robotic-assisted surgery, or more traditional open surgery. These procedures can range from removing polyps during a colonoscopy to complex resections of the colon, rectum, or anus.

Colorectal surgeons also work closely with other medical specialists, such as gastroenterologists, oncologists, and radiologists, to provide comprehensive care for their patients.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Sigmoidoscopy is a medical procedure that involves the insertion of a sigmoidoscope, a flexible tube with a light and camera at the end, into the rectum and lower colon (sigmoid colon) to examine these areas for any abnormalities such as inflammation, ulcers, polyps, or cancer. The procedure typically allows for the detection of issues in the sigmoid colon and rectum, and can help diagnose conditions such as inflammatory bowel disease, diverticulosis, or colorectal cancer.

There are two types of sigmoidoscopy: flexible sigmoidoscopy and rigid sigmoidoscopy. Flexible sigmoidoscopy is more commonly performed because it provides a better view of the lower colon and is less uncomfortable for the patient. Rigid sigmoidoscopy, on the other hand, uses a solid, inflexible tube and is typically used in specific situations such as the removal of foreign objects or certain types of polyps.

During the procedure, patients are usually positioned on their left side with their knees drawn up to their chest. The sigmoidoscope is gently inserted into the rectum and advanced through the lower colon while the doctor examines the lining for any abnormalities. Air may be introduced through the scope to help expand the colon and provide a better view. If polyps or other abnormal tissues are found, they can often be removed during the procedure for further examination and testing.

Sigmoidoscopy is generally considered a safe and well-tolerated procedure. Some patients may experience mild discomfort, bloating, or cramping during or after the exam, but these symptoms typically resolve on their own within a few hours.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Adenomatous polyps, also known as adenomas, are benign (noncancerous) growths that develop in the lining of the glandular tissue of certain organs, most commonly occurring in the colon and rectum. These polyps are composed of abnormal glandular cells that can grow excessively and form a mass.

Adenomatous polyps can vary in size, ranging from a few millimeters to several centimeters in diameter. They may be flat or have a stalk (pedunculated). While adenomas are generally benign, they can potentially undergo malignant transformation and develop into colorectal cancer over time if left untreated. The risk of malignancy increases with the size of the polyp and the presence of certain histological features, such as dysplasia (abnormal cell growth).

Regular screening for adenomatous polyps is essential to detect and remove them early, reducing the risk of colorectal cancer. Screening methods include colonoscopy, sigmoidoscopy, and stool-based tests.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Fluorouracil is a antineoplastic medication, which means it is used to treat cancer. It is a type of chemotherapy drug known as an antimetabolite. Fluorouracil works by interfering with the growth of cancer cells and ultimately killing them. It is often used to treat colon, esophageal, stomach, and breast cancers, as well as skin conditions such as actinic keratosis and superficial basal cell carcinoma. Fluorouracil may be given by injection or applied directly to the skin in the form of a cream.

It is important to note that fluorouracil can have serious side effects, including suppression of bone marrow function, mouth sores, stomach and intestinal ulcers, and nerve damage. It should only be used under the close supervision of a healthcare professional.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Intestinal polyps are abnormal growths that protrude from the lining of the intestines. They can occur in any part of the digestive tract, including the colon and rectum (colorectal polyps), small intestine, or stomach. These growths vary in size, shape, and number. Most intestinal polyps are benign, meaning they are not cancerous. However, some types of polyps, such as adenomatous polyps, can become cancerous over time if left untreated.

Intestinal polyps can be asymptomatic or cause symptoms like rectal bleeding, abdominal pain, changes in bowel habits, or anemia (in cases where there is chronic, slow bleeding). The exact cause of intestinal polyps is not fully understood, but factors such as age, family history, and certain genetic conditions can increase the risk of developing them. Regular screening exams, like colonoscopies, are essential for early detection and removal of polyps to prevent potential complications, including colorectal cancer.

Adenomatous Polyposis Coli (APC) is a genetic disorder characterized by the development of numerous adenomatous polyps in the colon and rectum. APC is caused by mutations in the APC gene, which is a tumor suppressor gene that helps regulate cell growth and division. When the APC gene is mutated, it can lead to uncontrolled cell growth and the development of polyps, which can eventually become cancerous.

Individuals with APC typically develop hundreds to thousands of polyps in their colon and rectum, usually beginning in adolescence or early adulthood. If left untreated, APC can lead to colorectal cancer in nearly all affected individuals by the age of 40.

APC is an autosomal dominant disorder, which means that a person has a 50% chance of inheriting the mutated gene from an affected parent. However, some cases of APC may also occur spontaneously due to new mutations in the APC gene. Treatment for APC typically involves surgical removal of the colon and rectum (colectomy) to prevent the development of colorectal cancer. Regular surveillance with colonoscopy is also recommended to monitor for the development of new polyps.

Organoplatinum compounds are a group of chemical substances that contain at least one carbon-platinum bond. These compounds have been widely studied and used in the field of medicine, particularly in cancer chemotherapy. The most well-known organoplatinum compound is cisplatin, which is a platinum-based drug used to treat various types of cancers such as testicular, ovarian, bladder, and lung cancers. Cisplatin works by forming crosslinks with the DNA of cancer cells, disrupting their ability to replicate and ultimately leading to cell death. Other examples of organoplatinum compounds used in cancer treatment include carboplatin and oxaliplatin.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Carcinoembryonic antigen (CEA) is a protein that is normally produced in small amounts during fetal development. In adults, low levels of CEA can be found in the blood, but elevated levels are typically associated with various types of cancer, particularly colon, rectal, and breast cancer.

Measurement of CEA levels in the blood is sometimes used as a tumor marker to monitor response to treatment, detect recurrence, or screen for secondary cancers in patients with a history of certain types of cancer. However, it's important to note that CEA is not a specific or sensitive indicator of cancer and can be elevated in various benign conditions such as inflammation, smoking, and some gastrointestinal diseases. Therefore, the test should be interpreted in conjunction with other clinical and diagnostic findings.

Leucovorin is the pharmaceutical name for a form of folic acid, also known as folinic acid. It is used in medicine as a medication to reduce the toxic effects of certain chemotherapy drugs, such as methotrexate, that work by blocking the action of folic acid in the body. Leucovorin is able to bypass this blockage and restore some of the necessary functions of folic acid, helping to prevent or reduce the severity of side effects like nausea, vomiting, and damage to the mucous membranes.

Leucovorin may also be used in combination with fluorouracil chemotherapy to enhance its effectiveness in treating certain types of cancer. It is important to note that leucovorin should only be used under the supervision of a healthcare professional, as it can interact with other medications and have potentially serious side effects if not used properly.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Medical mass screening, also known as population screening, is a public health service that aims to identify and detect asymptomatic individuals in a given population who have or are at risk of a specific disease. The goal is to provide early treatment, reduce morbidity and mortality, and prevent the spread of diseases within the community.

A mass screening program typically involves offering a simple, quick, and non-invasive test to a large number of people in a defined population, regardless of their risk factors or symptoms. Those who test positive are then referred for further diagnostic tests and appropriate medical interventions. Examples of mass screening programs include mammography for breast cancer detection, PSA (prostate-specific antigen) testing for prostate cancer, and fecal occult blood testing for colorectal cancer.

It is important to note that mass screening programs should be evidence-based, cost-effective, and ethically sound, with clear benefits outweighing potential harms. They should also consider factors such as the prevalence of the disease in the population, the accuracy and reliability of the screening test, and the availability and effectiveness of treatment options.

Microsatellite repeats, also known as short tandem repeats (STRs), are repetitive DNA sequences made up of units of 1-6 base pairs that are repeated in a head-to-tail manner. These repeats are spread throughout the human genome and are highly polymorphic, meaning they can have different numbers of repeat units in different individuals.

Microsatellites are useful as genetic markers because of their high degree of variability. They are commonly used in forensic science to identify individuals, in genealogy to trace ancestry, and in medical research to study genetic diseases and disorders. Mutations in microsatellite repeats have been associated with various neurological conditions, including Huntington's disease and fragile X syndrome.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

Camptothecin is a topoisomerase I inhibitor, which is a type of chemotherapeutic agent used in cancer treatment. It works by interfering with the function of an enzyme called topoisomerase I, which helps to uncoil DNA during cell division. By inhibiting this enzyme, camptothecin prevents the cancer cells from dividing and growing, ultimately leading to their death.

Camptothecin is found naturally in the bark and stem of the Camptotheca acuminata tree, also known as the "happy tree," which is native to China. It was first isolated in 1966 and has since been developed into several synthetic derivatives, including irinotecan and topotecan, which are used clinically to treat various types of cancer, such as colon, lung, and ovarian cancers.

Like other chemotherapeutic agents, camptothecin can have significant side effects, including nausea, vomiting, diarrhea, and myelosuppression (suppression of bone marrow function). It is important for patients receiving camptothecin-based therapies to be closely monitored by their healthcare team to manage these side effects effectively.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

MutS Homolog 2 (MSH2) Protein is a type of protein involved in the DNA repair process in cells. It is a member of the MutS family of proteins, which are responsible for identifying and correcting mistakes that occur during DNA replication. MSH2 forms a complex with another MutS homolog, MSH6, and this complex plays a crucial role in recognizing and binding to mismatched base pairs in the DNA. Once bound, the complex recruits other proteins to repair the damage and restore the integrity of the DNA. Defects in the MSH2 gene have been linked to an increased risk of certain types of cancer, including hereditary non-polyposis colorectal cancer (HNPCC) and uterine cancer.

HT-29 is a human colon adenocarcinoma cell line that is commonly used in research. These cells are derived from a colorectal cancer tumor and have the ability to differentiate into various cell types found in the intestinal mucosa, such as absorptive enterocytes and mucus-secreting goblet cells. HT-29 cells are often used to study the biology of colon cancer, including the effects of drugs on cancer cell growth and survival, as well as the role of various genes and signaling pathways in colorectal tumorigenesis.

It is important to note that when working with cell lines like HT-29, it is essential to use proper laboratory techniques and follow established protocols to ensure the integrity and reproducibility of experimental results. Additionally, researchers should regularly authenticate their cell lines to confirm their identity and verify that they are free from contamination with other cell types.

A colectomy is a surgical procedure in which all or part of the large intestine (colon) is removed. This surgery may be performed to treat or prevent various medical conditions, including colon cancer, inflammatory bowel disease, diverticulitis, and severe obstructions or injuries of the colon.

There are several types of colectomies, depending on how much of the colon is removed:

* Total colectomy: Removal of the entire colon.
* Partial colectomy: Removal of a portion of the colon.
* Hemicolectomy: Removal of one half of the colon.
* Sigmoidectomy: Removal of the sigmoid colon, which is the part of the colon that is closest to the rectum.

After the affected portion of the colon is removed, the remaining ends of the intestine are reconnected, allowing stool to pass through the digestive system as usual. In some cases, a temporary or permanent colostomy may be necessary, in which a surgical opening (stoma) is created in the abdominal wall and the end of the colon is attached to it, allowing stool to be collected in a pouch outside the body.

Colectomies are major surgeries that require general anesthesia and hospitalization. The recovery time can vary depending on the type of colectomy performed and the individual's overall health, but typically ranges from several weeks to a few months. Complications of colectomy may include bleeding, infection, leakage from the surgical site, bowel obstruction, and changes in bowel habits or function.

APC (Adenomatous Polyposis Coli) gene is a tumor suppressor gene that provides instructions for making a protein called adenomatous polyposis coli. This protein plays a crucial role in regulating the growth and division of cells in the colon and rectum. Specifically, it helps to maintain the stability of the cell's genetic material (DNA) by controlling the process of beta-catenin degradation.

When the APC gene is mutated or altered, it can lead to an accumulation of beta-catenin in the cell, which can result in uncontrolled cell growth and division. This can ultimately lead to the development of colon polyps, which are benign growths that can become cancerous over time if left untreated.

Mutations in the APC gene are associated with several inherited cancer syndromes, including familial adenomatous polyposis (FAP) and attenuated FAP (AFAP). These conditions are characterized by the development of numerous colon polyps at a young age, which can increase the risk of developing colorectal cancer.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

Local neoplasm recurrence is the return or regrowth of a tumor in the same location where it was originally removed or treated. This means that cancer cells have survived the initial treatment and started to grow again in the same area. It's essential to monitor and detect any local recurrence as early as possible, as it can affect the prognosis and may require additional treatment.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Intestinal neoplasms refer to abnormal growths in the tissues of the intestines, which can be benign or malignant. These growths are called neoplasms and they result from uncontrolled cell division. In the case of intestinal neoplasms, these growths occur in the small intestine, large intestine (colon), rectum, or appendix.

Benign intestinal neoplasms are not cancerous and often do not invade surrounding tissues or spread to other parts of the body. However, they can still cause problems if they grow large enough to obstruct the intestines or cause bleeding. Common types of benign intestinal neoplasms include polyps, leiomyomas, and lipomas.

Malignant intestinal neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to other parts of the body. The most common type of malignant intestinal neoplasm is adenocarcinoma, which arises from the glandular cells lining the inside of the intestines. Other types of malignant intestinal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Symptoms of intestinal neoplasms can vary depending on their size, location, and type. Common symptoms include abdominal pain, bloating, changes in bowel habits, rectal bleeding, weight loss, and fatigue. If you experience any of these symptoms, it is important to seek medical attention promptly.

HCT116 cells are a type of human colon cancer cell line that is widely used in scientific research. They were originally established in the early 1980s from a primary colon tumor that had metastasized to the liver. HCT116 cells are known for their stability, robust growth, and susceptibility to various genetic manipulations, making them a popular choice for studying cancer biology, drug discovery, and gene function.

These cells have several important features that make them useful in research. For example, they harbor mutations in key genes involved in colorectal cancer development, such as the adenomatous polyposis coli (APC) gene and the KRAS oncogene. Additionally, HCT116 cells can be easily cultured in the lab and are amenable to a variety of experimental techniques, including genetic modification, drug screening, and protein analysis.

It is important to note that while HCT116 cells provide valuable insights into colon cancer biology, they represent only one type of cancer cell line, and their behavior may not necessarily reflect the complexity of human tumors in vivo. Therefore, researchers must exercise caution when interpreting results obtained from these cells and consider other complementary approaches to validate their findings.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Rectal diseases refer to conditions that affect the structure or function of the rectum, which is the lower end of the large intestine, just above the anus. The rectum serves as a storage area for stool before it is eliminated from the body. Some common rectal diseases include:

1. Hemorrhoids: Swollen veins in the rectum or anus that can cause pain, itching, bleeding, and discomfort.
2. Rectal cancer: Abnormal growth of cells in the rectum that can invade and destroy nearby tissue and spread to other parts of the body.
3. Anal fissures: Small tears in the lining of the anus that can cause pain, bleeding, and itching.
4. Rectal prolapse: A condition where the rectum slips outside the anus, causing discomfort, fecal incontinence, and other symptoms.
5. Inflammatory bowel disease (IBD): A group of chronic inflammatory conditions that affect the digestive tract, including the rectum, such as Crohn's disease and ulcerative colitis.
6. Rectal abscess: A collection of pus in the rectum caused by an infection, which can cause pain, swelling, and fever.
7. Fistula-in-ano: An abnormal connection between the rectum and the skin around the anus, which can cause drainage of pus or stool.
8. Rectal foreign bodies: Objects that are accidentally or intentionally inserted into the rectum and can cause injury, infection, or obstruction.

These are just a few examples of rectal diseases, and there are many other conditions that can affect the rectum. If you experience any symptoms related to the rectum, it is important to seek medical attention from a healthcare professional for proper diagnosis and treatment.

Ras genes are a group of genes that encode for proteins involved in cell signaling pathways that regulate cell growth, differentiation, and survival. Mutations in Ras genes have been associated with various types of cancer, as well as other diseases such as developmental disorders and autoimmune diseases. The Ras protein family includes H-Ras, K-Ras, and N-Ras, which are activated by growth factor receptors and other signals to activate downstream effectors involved in cell proliferation and survival. Abnormal activation of Ras signaling due to mutations or dysregulation can contribute to tumor development and progression.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

DNA methylation is a process by which methyl groups (-CH3) are added to the cytosine ring of DNA molecules, often at the 5' position of cytospine phosphate-deoxyguanosine (CpG) dinucleotides. This modification is catalyzed by DNA methyltransferase enzymes and results in the formation of 5-methylcytosine.

DNA methylation plays a crucial role in the regulation of gene expression, genomic imprinting, X chromosome inactivation, and suppression of transposable elements. Abnormal DNA methylation patterns have been associated with various diseases, including cancer, where tumor suppressor genes are often silenced by promoter methylation.

In summary, DNA methylation is a fundamental epigenetic modification that influences gene expression and genome stability, and its dysregulation has important implications for human health and disease.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

PROTEIN B-RAF, also known as serine/threonine-protein kinase B-Raf, is a crucial enzyme that helps regulate the cell growth signaling pathway in the body. It is a type of proto-oncogene protein, which means it has the potential to contribute to cancer development if mutated or overexpressed.

The B-RAF protein is part of the RAS/MAPK signaling pathway, which plays a critical role in controlling cell growth, division, and survival. When activated by upstream signals, B-RAF activates another kinase called MEK, which then activates ERK, leading to the regulation of various genes involved in cell growth and differentiation.

Mutations in the B-RAF gene can lead to constitutive activation of the protein, causing uncontrolled cell growth and division, which can contribute to the development of various types of cancer, including melanoma, colon cancer, and thyroid cancer. The most common mutation in the B-RAF gene is V600E, which affects around 8% of all human cancers.

Therefore, B-RAF inhibitors have been developed as targeted therapies for cancer treatment, particularly for melanoma patients with B-RAF V600E mutations. These drugs work by blocking the activity of the mutated B-RAF protein, thereby preventing uncontrolled cell growth and division.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

In epidemiology, the incidence of a disease is defined as the number of new cases of that disease within a specific population over a certain period of time. It is typically expressed as a rate, with the number of new cases in the numerator and the size of the population at risk in the denominator. Incidence provides information about the risk of developing a disease during a given time period and can be used to compare disease rates between different populations or to monitor trends in disease occurrence over time.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Beta-catenin is a protein that plays a crucial role in gene transcription and cell-cell adhesion. It is a key component of the Wnt signaling pathway, which regulates various processes such as cell proliferation, differentiation, and migration during embryonic development and tissue homeostasis in adults.

In the absence of Wnt signals, beta-catenin forms a complex with other proteins, including adenomatous polyposis coli (APC) and axin, which targets it for degradation by the proteasome. When Wnt ligands bind to their receptors, this complex is disrupted, allowing beta-catenin to accumulate in the cytoplasm and translocate to the nucleus. In the nucleus, beta-catenin interacts with T cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors to activate the transcription of target genes involved in cell fate determination, survival, and proliferation.

Mutations in the genes encoding components of the Wnt signaling pathway, including beta-catenin, have been implicated in various human diseases, such as cancer, developmental disorders, and degenerative conditions.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

DNA mismatch repair (MMR) is a cellular process that helps to correct errors that occur during DNA replication and recombination. This mechanism plays a critical role in maintaining the stability of the genome by reducing the rate of mutations.

The MMR system recognizes and repairs base-base mismatches and small insertions or deletions (indels) that can arise due to slippage of DNA polymerase during replication. The process involves several proteins, including MutSα or MutSβ, which recognize the mismatch, and MutLα, which acts as a endonuclease to cleave the DNA near the mismatch. Excision of the mismatched region is then carried out by exonucleases, followed by resynthesis of the repaired strand using the correct template.

Defects in MMR genes have been linked to various human diseases, including hereditary nonpolyposis colorectal cancer (HNPCC) and other types of cancer. In HNPCC, mutations in MMR genes lead to an accumulation of mutations in critical genes, which can ultimately result in the development of cancer.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Ras proteins are a group of small GTPases that play crucial roles as regulators of intracellular signaling pathways in cells. They are involved in various cellular processes, such as cell growth, differentiation, and survival. Ras proteins cycle between an inactive GDP-bound state and an active GTP-bound state to transmit signals from membrane receptors to downstream effectors. Mutations in Ras genes can lead to constitutive activation of Ras proteins, which has been implicated in various human cancers and developmental disorders.

A germ-line mutation is a genetic change that occurs in the egg or sperm cells (gametes), and thus can be passed down from parents to their offspring. These mutations are present throughout the entire body of the offspring, as they are incorporated into the DNA of every cell during embryonic development.

Germ-line mutations differ from somatic mutations, which occur in other cells of the body that are not involved in reproduction. While somatic mutations can contribute to the development of cancer and other diseases within an individual, they are not passed down to future generations.

It's important to note that germ-line mutations can have significant implications for medical genetics and inherited diseases. For example, if a parent has a germ-line mutation in a gene associated with a particular disease, their offspring may have an increased risk of developing that disease as well.

Sigmoid neoplasms refer to abnormal growths or tumors in the sigmoid colon, which is the lower portion of the large intestine that extends from the descending colon to the rectum. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms, such as adenomas, are typically removed through a polypectomy during a colonoscopy to prevent their potential transformation into malignant tumors. Malignant neoplasms, on the other hand, are often referred to as sigmoid colon cancers and can be classified into different types based on their cellular origin, such as adenocarcinomas, lymphomas, carcinoids, or sarcomas.

Adenocarcinomas are the most common type of sigmoid neoplasm, accounting for more than 95% of all cases. These tumors originate from the glandular cells lining the colon's inner surface and can invade surrounding tissues, leading to local spread or distant metastasis if left untreated. Early detection and removal of sigmoid neoplasms significantly improve treatment outcomes and overall prognosis.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Genetic predisposition to disease refers to an increased susceptibility or vulnerability to develop a particular illness or condition due to inheriting specific genetic variations or mutations from one's parents. These genetic factors can make it more likely for an individual to develop a certain disease, but it does not guarantee that the person will definitely get the disease. Environmental factors, lifestyle choices, and interactions between genes also play crucial roles in determining if a genetically predisposed person will actually develop the disease. It is essential to understand that having a genetic predisposition only implies a higher risk, not an inevitable outcome.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Colonic diseases refer to a group of medical conditions that affect the colon, also known as the large intestine or large bowel. The colon is the final segment of the digestive system, responsible for absorbing water and electrolytes, and storing and eliminating waste products.

Some common colonic diseases include:

1. Inflammatory bowel disease (IBD): This includes conditions such as Crohn's disease and ulcerative colitis, which cause inflammation and irritation in the lining of the digestive tract.
2. Diverticular disease: This occurs when small pouches called diverticula form in the walls of the colon, leading to symptoms such as abdominal pain, bloating, and changes in bowel movements.
3. Colorectal cancer: This is a type of cancer that develops in the colon or rectum, often starting as benign polyps that grow and become malignant over time.
4. Irritable bowel syndrome (IBS): This is a functional gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel movements, but without any underlying structural or inflammatory causes.
5. Constipation: This is a common condition characterized by infrequent bowel movements, difficulty passing stools, or both.
6. Infectious colitis: This occurs when the colon becomes infected with bacteria, viruses, or parasites, leading to symptoms such as diarrhea, abdominal cramps, and fever.

Treatment for colonic diseases varies depending on the specific condition and its severity. Treatment options may include medications, lifestyle changes, surgery, or a combination of these approaches.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

A precancerous condition, also known as a premalignant condition, is a state of abnormal cellular growth and development that has a higher-than-normal potential to progress into cancer. These conditions are characterized by the presence of certain anomalies in the cells, such as dysplasia (abnormal changes in cell shape or size), which can indicate an increased risk for malignant transformation.

It is important to note that not all precancerous conditions will eventually develop into cancer, and some may even regress on their own. However, individuals with precancerous conditions are often at a higher risk of developing cancer compared to the general population. Regular monitoring and appropriate medical interventions, if necessary, can help manage this risk and potentially prevent or detect cancer at an early stage when it is more treatable.

Examples of precancerous conditions include:

1. Dysplasia in the cervix (cervical intraepithelial neoplasia or CIN)
2. Atypical ductal hyperplasia or lobular hyperplasia in the breast
3. Actinic keratosis on the skin
4. Leukoplakia in the mouth
5. Barrett's esophagus in the digestive tract

Regular medical check-ups, screenings, and lifestyle modifications are crucial for individuals with precancerous conditions to monitor their health and reduce the risk of cancer development.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Stomach neoplasms refer to abnormal growths in the stomach that can be benign or malignant. They include a wide range of conditions such as:

1. Gastric adenomas: These are benign tumors that develop from glandular cells in the stomach lining.
2. Gastrointestinal stromal tumors (GISTs): These are rare tumors that can be found in the stomach and other parts of the digestive tract. They originate from the stem cells in the wall of the digestive tract.
3. Leiomyomas: These are benign tumors that develop from smooth muscle cells in the stomach wall.
4. Lipomas: These are benign tumors that develop from fat cells in the stomach wall.
5. Neuroendocrine tumors (NETs): These are tumors that develop from the neuroendocrine cells in the stomach lining. They can be benign or malignant.
6. Gastric carcinomas: These are malignant tumors that develop from the glandular cells in the stomach lining. They are the most common type of stomach neoplasm and include adenocarcinomas, signet ring cell carcinomas, and others.
7. Lymphomas: These are malignant tumors that develop from the immune cells in the stomach wall.

Stomach neoplasms can cause various symptoms such as abdominal pain, nausea, vomiting, weight loss, and difficulty swallowing. The diagnosis of stomach neoplasms usually involves a combination of imaging tests, endoscopy, and biopsy. Treatment options depend on the type and stage of the neoplasm and may include surgery, chemotherapy, radiation therapy, or targeted therapy.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

A cohort study is a type of observational study in which a group of individuals who share a common characteristic or exposure are followed up over time to determine the incidence of a specific outcome or outcomes. The cohort, or group, is defined based on the exposure status (e.g., exposed vs. unexposed) and then monitored prospectively to assess for the development of new health events or conditions.

Cohort studies can be either prospective or retrospective in design. In a prospective cohort study, participants are enrolled and followed forward in time from the beginning of the study. In contrast, in a retrospective cohort study, researchers identify a cohort that has already been assembled through medical records, insurance claims, or other sources and then look back in time to assess exposure status and health outcomes.

Cohort studies are useful for establishing causality between an exposure and an outcome because they allow researchers to observe the temporal relationship between the two. They can also provide information on the incidence of a disease or condition in different populations, which can be used to inform public health policy and interventions. However, cohort studies can be expensive and time-consuming to conduct, and they may be subject to bias if participants are not representative of the population or if there is loss to follow-up.

Pancreatic ductal carcinoma (PDC) is a specific type of cancer that forms in the ducts that carry digestive enzymes out of the pancreas. It's the most common form of exocrine pancreatic cancer, making up about 90% of all cases.

The symptoms of PDC are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), unexplained weight loss, and changes in bowel movements. These symptoms can be similar to those caused by other less serious conditions, which can make diagnosis difficult.

Pancreatic ductal carcinoma is often aggressive and difficult to treat. The prognosis for PDC is generally poor, with a five-year survival rate of only about 9%. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches. However, because PDC is often not detected until it has advanced, treatment is frequently focused on palliative care to relieve symptoms and improve quality of life.

Adenomatous polyposis coli (APC) protein is a tumor suppressor protein that plays a crucial role in regulating cell growth and division. It is encoded by the APC gene, which is located on chromosome 5. The APC protein helps to prevent excessive cell growth and division by inhibiting the activity of a protein called beta-catenin, which promotes cell growth and division when activated.

In individuals with certain genetic disorders, such as familial adenomatous polyposis (FAP), mutations in the APC gene can lead to the production of a defective APC protein or no APC protein at all. This can result in uncontrolled cell growth and division, leading to the development of numerous benign tumors called polyps in the colon and rectum. Over time, some of these polyps may become cancerous, leading to colorectal cancer if left untreated.

APC protein also has other functions in the body, including regulating cell migration and adhesion, and playing a role in maintaining the stability of the cytoskeleton. Mutations in the APC gene have been linked to other types of cancer besides colorectal cancer, including breast, lung, and ovarian cancers.

Adenocarcinoma, papillary is a type of cancer that begins in the glandular cells and grows in a finger-like projection (called a papilla). This type of cancer can occur in various organs, including the lungs, pancreas, thyroid, and female reproductive system. The prognosis and treatment options for papillary adenocarcinoma depend on several factors, such as the location and stage of the tumor, as well as the patient's overall health. It is important to consult with a healthcare professional for an accurate diagnosis and personalized treatment plan.

Proto-oncogene proteins are normal cellular proteins that play crucial roles in various cellular processes, such as signal transduction, cell cycle regulation, and apoptosis (programmed cell death). They are involved in the regulation of cell growth, differentiation, and survival under physiological conditions.

When proto-oncogene proteins undergo mutations or aberrations in their expression levels, they can transform into oncogenic forms, leading to uncontrolled cell growth and division. These altered proteins are then referred to as oncogene products or oncoproteins. Oncogenic mutations can occur due to various factors, including genetic predisposition, environmental exposures, and aging.

Examples of proto-oncogene proteins include:

1. Ras proteins: Involved in signal transduction pathways that regulate cell growth and differentiation. Activating mutations in Ras genes are found in various human cancers.
2. Myc proteins: Regulate gene expression related to cell cycle progression, apoptosis, and metabolism. Overexpression of Myc proteins is associated with several types of cancer.
3. EGFR (Epidermal Growth Factor Receptor): A transmembrane receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation. Mutations or overexpression of EGFR are linked to various malignancies, such as lung cancer and glioblastoma.
4. Src family kinases: Intracellular tyrosine kinases that regulate signal transduction pathways involved in cell proliferation, survival, and migration. Dysregulation of Src family kinases is implicated in several types of cancer.
5. Abl kinases: Cytoplasmic tyrosine kinases that regulate various cellular processes, including cell growth, differentiation, and stress responses. Aberrant activation of Abl kinases, as seen in chronic myelogenous leukemia (CML), leads to uncontrolled cell proliferation.

Understanding the roles of proto-oncogene proteins and their dysregulation in cancer development is essential for developing targeted cancer therapies that aim to inhibit or modulate these aberrant signaling pathways.

A neoplasm of vascular tissue is an abnormal growth or mass of cells in the blood vessels or lymphatic vessels. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms, such as hemangiomas and lymphangiomas, are typically not harmful and may not require treatment. However, they can cause symptoms if they grow large enough to press on nearby organs or tissues. Malignant neoplasms, such as angiosarcomas, are cancerous and can invade and destroy surrounding tissue, as well as spread (metastasize) to other parts of the body. Treatment for vascular tissue neoplasms depends on the type, size, location, and stage of the growth, and may include surgery, radiation therapy, chemotherapy, or a combination of these.

Lymphatic metastasis is the spread of cancer cells from a primary tumor to distant lymph nodes through the lymphatic system. It occurs when malignant cells break away from the original tumor, enter the lymphatic vessels, and travel to nearby or remote lymph nodes. Once there, these cancer cells can multiply and form new tumors, leading to further progression of the disease. Lymphatic metastasis is a common way for many types of cancer to spread and can have significant implications for prognosis and treatment strategies.

Radiation-induced neoplasms are a type of cancer or tumor that develops as a result of exposure to ionizing radiation. Ionizing radiation is radiation with enough energy to remove tightly bound electrons from atoms or molecules, leading to the formation of ions. This type of radiation can damage DNA and other cellular structures, which can lead to mutations and uncontrolled cell growth, resulting in the development of a neoplasm.

Radiation-induced neoplasms can occur after exposure to high levels of ionizing radiation, such as that received during radiation therapy for cancer treatment or from nuclear accidents. The risk of developing a radiation-induced neoplasm depends on several factors, including the dose and duration of radiation exposure, the type of radiation, and the individual's genetic susceptibility to radiation-induced damage.

Radiation-induced neoplasms can take many years to develop after initial exposure to ionizing radiation, and they often occur at the site of previous radiation therapy. Common types of radiation-induced neoplasms include sarcomas, carcinomas, and thyroid cancer. It is important to note that while ionizing radiation can increase the risk of developing cancer, the overall risk is still relatively low, especially when compared to other well-established cancer risk factors such as smoking and exposure to certain chemicals.

Eye neoplasms, also known as ocular tumors or eye cancer, refer to abnormal growths of tissue in the eye. These growths can be benign (non-cancerous) or malignant (cancerous). Eye neoplasms can develop in various parts of the eye, including the eyelid, conjunctiva, cornea, iris, ciliary body, choroid, retina, and optic nerve.

Benign eye neoplasms are typically slow-growing and do not spread to other parts of the body. They may cause symptoms such as vision changes, eye pain, or a noticeable mass in the eye. Treatment options for benign eye neoplasms include monitoring, surgical removal, or radiation therapy.

Malignant eye neoplasms, on the other hand, can grow and spread rapidly to other parts of the body. They may cause symptoms such as vision changes, eye pain, floaters, or flashes of light. Treatment options for malignant eye neoplasms depend on the type and stage of cancer but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

It is important to note that early detection and treatment of eye neoplasms can improve outcomes and prevent complications. Regular eye exams with an ophthalmologist are recommended for early detection and prevention of eye diseases, including eye neoplasms.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.

Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Immunoenzyme techniques are a group of laboratory methods used in immunology and clinical chemistry that combine the specificity of antibody-antigen reactions with the sensitivity and amplification capabilities of enzyme reactions. These techniques are primarily used for the detection, quantitation, or identification of various analytes (such as proteins, hormones, drugs, viruses, or bacteria) in biological samples.

In immunoenzyme techniques, an enzyme is linked to an antibody or antigen, creating a conjugate. This conjugate then interacts with the target analyte in the sample, forming an immune complex. The presence and amount of this immune complex can be visualized or measured by detecting the enzymatic activity associated with it.

There are several types of immunoenzyme techniques, including:

1. Enzyme-linked Immunosorbent Assay (ELISA): A widely used method for detecting and quantifying various analytes in a sample. In ELISA, an enzyme is attached to either the capture antibody or the detection antibody. After the immune complex formation, a substrate is added that reacts with the enzyme, producing a colored product that can be measured spectrophotometrically.
2. Immunoblotting (Western blot): A method used for detecting specific proteins in a complex mixture, such as a protein extract from cells or tissues. In this technique, proteins are separated by gel electrophoresis and transferred to a membrane, where they are probed with an enzyme-conjugated antibody directed against the target protein.
3. Immunohistochemistry (IHC): A method used for detecting specific antigens in tissue sections or cells. In IHC, an enzyme-conjugated primary or secondary antibody is applied to the sample, and the presence of the antigen is visualized using a chromogenic substrate that produces a colored product at the site of the antigen-antibody interaction.
4. Immunofluorescence (IF): A method used for detecting specific antigens in cells or tissues by employing fluorophore-conjugated antibodies. The presence of the antigen is visualized using a fluorescence microscope.
5. Enzyme-linked immunosorbent assay (ELISA): A method used for detecting and quantifying specific antigens or antibodies in liquid samples, such as serum or culture supernatants. In ELISA, an enzyme-conjugated detection antibody is added after the immune complex formation, and a substrate is added that reacts with the enzyme to produce a colored product that can be measured spectrophotometrically.

These techniques are widely used in research and diagnostic laboratories for various applications, including protein characterization, disease diagnosis, and monitoring treatment responses.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Antimetabolites are a class of antineoplastic (chemotherapy) drugs that interfere with the metabolism of cancer cells and inhibit their growth and proliferation. These agents are structurally similar to naturally occurring metabolites, such as amino acids, nucleotides, and folic acid, which are essential for cellular replication and growth. Antimetabolites act as false analogs and get incorporated into the growing cells' DNA or RNA, causing disruption of the normal synthesis process, leading to cell cycle arrest and apoptosis (programmed cell death).

Examples of antimetabolite drugs include:

1. Folate antagonists: Methotrexate, Pemetrexed
2. Purine analogs: Mercaptopurine, Thioguanine, Fludarabine, Cladribine
3. Pyrimidine analogs: 5-Fluorouracil (5-FU), Capecitabine, Cytarabine, Gemcitabine

These drugs are used to treat various types of cancers, such as leukemias, lymphomas, breast, ovarian, and gastrointestinal cancers. Due to their mechanism of action, antimetabolites can also affect normal, rapidly dividing cells in the body, leading to side effects like myelosuppression (decreased production of blood cells), mucositis (inflammation and ulceration of the gastrointestinal tract), and alopecia (hair loss).

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Hepatectomy is a surgical procedure that involves the removal of part or all of the liver. This procedure can be performed for various reasons, such as removing cancerous or non-cancerous tumors, treating liver trauma, or donating a portion of the liver to another person in need of a transplant (live donor hepatectomy). The extent of the hepatectomy depends on the medical condition and overall health of the patient. It is a complex procedure that requires significant expertise and experience from the surgical team due to the liver's unique anatomy, blood supply, and regenerative capabilities.

Computed tomographic colonography (CTC), also known as virtual colonoscopy, is a medical imaging technique that uses computed tomography (CT) scans to produce detailed images of the large intestine (colon) and rectum. In CTC, specialized software creates two- and three-dimensional images of the colon's inner surface, allowing healthcare providers to examine the colon for polyps, tumors, and other abnormalities.

During a CTC procedure, patients are usually given a mild laxative and asked to follow a clear liquid diet beforehand to clean out the colon. A small tube is inserted into the rectum to inflate the colon with air or carbon dioxide, making it easier to visualize any abnormalities. The patient lies on their back and then their stomach while the CT scanner takes multiple images of the abdomen and pelvis from different angles.

CTC has several advantages over traditional colonoscopy, including less invasiveness, lower risk of complications, faster recovery time, and the ability to examine the entire colon without missing any areas. However, if polyps or other abnormalities are detected during a CTC, a follow-up diagnostic colonoscopy may be necessary for removal or further evaluation.

It is important to note that CTC does not replace traditional colonoscopy as a screening tool for colorectal cancer. While it has similar accuracy in detecting large polyps and cancers, its ability to detect smaller polyps is less reliable compared to optical colonoscopy. Therefore, guidelines recommend using CTC as an alternative option for individuals who cannot or do not wish to undergo traditional colonoscopy, or as a supplemental screening tool for those at higher risk of colorectal cancer.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Loss of Heterozygosity (LOH) is a term used in genetics to describe the loss of one copy of a gene or a segment of a chromosome, where there was previously a pair of different genes or chromosomal segments (heterozygous). This can occur due to various genetic events such as mutation, deletion, or mitotic recombination.

LOH is often associated with the development of cancer, as it can lead to the loss of tumor suppressor genes, which normally help to regulate cell growth and division. When both copies of a tumor suppressor gene are lost or inactivated, it can result in uncontrolled cell growth and the formation of a tumor.

In medical terms, LOH is used as a biomarker for cancer susceptibility, progression, and prognosis. It can also be used to identify individuals who may be at increased risk for certain types of cancer, or to monitor patients for signs of cancer recurrence.

Adaptor proteins are a type of protein that play a crucial role in intracellular signaling pathways by serving as a link between different components of the signaling complex. Specifically, "signal transducing adaptor proteins" refer to those adaptor proteins that are involved in signal transduction processes, where they help to transmit signals from the cell surface receptors to various intracellular effectors. These proteins typically contain modular domains that allow them to interact with multiple partners, thereby facilitating the formation of large signaling complexes and enabling the integration of signals from different pathways.

Signal transducing adaptor proteins can be classified into several families based on their structural features, including the Src homology 2 (SH2) domain, the Src homology 3 (SH3) domain, and the phosphotyrosine-binding (PTB) domain. These domains enable the adaptor proteins to recognize and bind to specific motifs on other signaling molecules, such as receptor tyrosine kinases, G protein-coupled receptors, and cytokine receptors.

One well-known example of a signal transducing adaptor protein is the growth factor receptor-bound protein 2 (Grb2), which contains an SH2 domain that binds to phosphotyrosine residues on activated receptor tyrosine kinases. Grb2 also contains an SH3 domain that interacts with proline-rich motifs on other signaling proteins, such as the guanine nucleotide exchange factor SOS. This interaction facilitates the activation of the Ras small GTPase and downstream signaling pathways involved in cell growth, differentiation, and survival.

Overall, signal transducing adaptor proteins play a critical role in regulating various cellular processes by modulating intracellular signaling pathways in response to extracellular stimuli. Dysregulation of these proteins has been implicated in various diseases, including cancer and inflammatory disorders.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Neoplasms in muscle tissue refer to abnormal and excessive growths of muscle cells that can be benign or malignant. These growths can arise from any of the three types of muscle tissue: skeletal, cardiac, or smooth muscle. Neoplasms in muscle tissue are classified based on their origin, behavior, and histological features.

Benign neoplasms in muscle tissue include leiomyomas (smooth muscle), rhabdomyomas (skeletal muscle), and myxomas (cardiac muscle). These tumors are usually slow-growing and do not invade surrounding tissues or spread to other parts of the body.

Malignant neoplasms in muscle tissue, also known as sarcomas, include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), and angiosarcoma (cardiac muscle). These tumors are aggressive, invasive, and have the potential to metastasize to other parts of the body.

Symptoms of neoplasms in muscle tissue depend on their location, size, and type. They may include a painless or painful mass, weakness, fatigue, weight loss, and difficulty swallowing or breathing. Treatment options for neoplasms in muscle tissue include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type, stage, location, and patient's overall health condition.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

A base pair mismatch is a type of mutation that occurs during the replication or repair of DNA, where two incompatible nucleotides pair up instead of the usual complementary bases (adenine-thymine or cytosine-guanine). This can result in the substitution of one base pair for another and may lead to changes in the genetic code, potentially causing errors in protein synthesis and possibly contributing to genetic disorders or diseases, including cancer.

Duodenal neoplasms refer to abnormal growths in the duodenum, which is the first part of the small intestine that receives digestive secretions from the pancreas and bile duct. These growths can be benign or malignant (cancerous).

Benign neoplasms include adenomas, leiomyomas, lipomas, and hamartomas. They are usually slow-growing and do not spread to other parts of the body. However, they may cause symptoms such as abdominal pain, bleeding, or obstruction of the intestine.

Malignant neoplasms include adenocarcinomas, neuroendocrine tumors (carcinoids), lymphomas, and sarcomas. They are more aggressive and can invade surrounding tissues and spread to other parts of the body. Symptoms may include abdominal pain, weight loss, jaundice, anemia, or bowel obstruction.

The diagnosis of duodenal neoplasms is usually made through imaging tests such as CT scans, MRI, or endoscopy with biopsy. Treatment depends on the type and stage of the tumor and may include surgery, chemotherapy, radiation therapy, or a combination of these modalities.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

Neoplastic cell transformation is a process in which a normal cell undergoes genetic alterations that cause it to become cancerous or malignant. This process involves changes in the cell's DNA that result in uncontrolled cell growth and division, loss of contact inhibition, and the ability to invade surrounding tissues and metastasize (spread) to other parts of the body.

Neoplastic transformation can occur as a result of various factors, including genetic mutations, exposure to carcinogens, viral infections, chronic inflammation, and aging. These changes can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, which regulate cell growth and division.

The transformation of normal cells into cancerous cells is a complex and multi-step process that involves multiple genetic and epigenetic alterations. It is characterized by several hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.

Neoplastic cell transformation is a fundamental concept in cancer biology and is critical for understanding the molecular mechanisms underlying cancer development and progression. It also has important implications for cancer diagnosis, prognosis, and treatment, as identifying the specific genetic alterations that underlie neoplastic transformation can help guide targeted therapies and personalized medicine approaches.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Jin H, Leng Q, Li C (August 2012). "Dietary flavonoid for preventing colorectal neoplasms". Colorectal Cancer Group. The ... "Red Meat (Beef, Pork, Lamb): Increases Risk of Colorectal Cancer". aicr.org. Retrieved 24 April 2023. Park S, Bae J, Nam BH, ... There is strong evidence that processed meat and red meat intake increases risk of colorectal cancer. Aflatoxin B1, a frequent ... The Western pattern diet has been generally linked to increased risk for colorectal cancer. Meta-analyses have found that diet ...
2003). "Down-regulation of drs mRNA in colorectal neoplasms". Jpn. J. Cancer Res. 93 (8): 888-93. doi:10.1111/j.1349-7006.2002. ...
... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ... Angiodysplasia of the colon Appendicitis Chronic functional abdominal pain Colitis Colorectal cancer Colorectal polyp ... Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A (March 1, 2017). "Colorectal cancer statistics". CA ... Tepus, M; Yau, TO (20 May 2020). "Non-Invasive Colorectal Cancer Screening: An Overview". Gastrointestinal Tumors. 7 (3): 62-73 ...
Tse, G; Eslick, G.D. (2014). "Cruciferous vegetables and risk of colorectal neoplasms: a systematic review and meta-analysis". ...
March 2008). "Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults". JAMA ... Individuals infected with H. pylori may also develop colorectal or gastric polyps, i.e. non-cancerous growths of tissue ... Colorectal Disease. 15 (7): e352-64. doi:10.1111/codi.12284. PMID 23672575. S2CID 5444584. "Helicobacter pylori" (PDF). cdc.gov ... gastric outlet obstruction while colorectal polyps may be the cause of rectal bleeding, anemia, constipation, diarrhea, weight ...
Colorectal cancer is the most common visceral neoplasm in Muir-Torre syndrome patients. The syndrome is named for Edward ... Along with neoplasms of the sebaceous gland, this patient developed cerebral neoplasms, characteristic of Turcot syndrome. ... Age of onset of first sebaceous neoplasm: 2 = 2 points. Personal history of Lynch related cancers: No = 0 points, Yes = 1 point ... They include the following: 3 or more relatives with an HNPCC-associated cancer (i.e., colorectal, cancer of the endometrium, ...
... mRNA expression is reduced in colorectal neoplasms due to methylation of the promoter region of MBD4. A majority of ... In colorectal cancers with mutations in MMR genes, co-occurrence of MBD4 mutations were found in 27% of cancers. ... For example, nearly 50% of somatic mutations of the tumor suppressor gene p53 in colorectal cancer are G:C to A:T transitions ... Mutation of MBD4 occurs in about 4% of colorectal cancers. MBD4 mutations also occur in tumor samples of melanoma, ovarian, ...
"A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms". ...
MBD4 expression is reduced in almost all colorectal neoplasms due to methylation of the promoter region of MBD4. Also MBD4 is ... For example, nearly 50% of somatic mutations of the tumor suppressor gene p53 in colorectal cancer are G:C to A:T transitions ... NEIL1 was also one of six DNA repair genes found to be hypermethylated in their promoter regions in colorectal cancer. Lindahl ... This finding suggests that epigenetic silencing of MBD4 is an early step in colorectal carcinogenesis. In a Chinese population ...
MBD4 expression is reduced in almost all colorectal neoplasms due to methylation of the promoter region of MBD4. Also MBD4 is ... For example, nearly 50% of somatic mutations of the tumor suppressor gene p53 in colorectal cancer are G:C to A:T transitions ... NEIL1 was also one of six DNA repair genes found to be hypermethylated in their promoter regions in colorectal cancer. Active ... This finding suggests that epigenetic silencing of MBD4 is an early step in colorectal carcinogenesis. In a Chinese population ...
The incidence of MTS in patients with sebaceous neoplasms as high as 14 to 50%. Besides mutations in mismatch repair genes, Wnt ... the most common being colorectal adenocarcinoma. MTS results from defects in DNA mismatch repair genes, MLH1, MSH2, and MSH6, ... SGc accounts for approximately 0.7% of all skin cancers and 0.2 to 4.6% of all malignant cutaneous neoplasms. Notable risk ... While there are markedly increased rates of cutaneous neoplasms in solid organ transplant recipients, there is evidence to ...
People with BHD were once thought to be at higher risk for colorectal polyps and neoplasms, but this has been disproven. The ... neoplasms, and cysts, Autosomal dominant disorders, Syndromes with tumors, Syndromes affecting the lung, Rare syndromes). ... colorectal cancer, sarcoma of the leg, lung cancer, melanoma, dermatofibrosarcoma protuberans, basal cell carcinoma, cutaneous ...
... and left-sided colorectal neoplasms after colonoscopy: population-based study". J Natl Cancer Inst. 102 (2): 89-95. doi:10.1093 ... Colonoscopy is one of the colorectal cancer screening tests available to people in the US who are 45 years of age and older. ... 2017). "Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on ... This interval does not apply to people at high risk of colorectal cancer or those who experience symptoms of the disease.) The ...
"NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor ... of the neoplasms associated with the BRD4-NUTM1 fusion gene. These questions also apply to a wide range of neoplasms that have ... A recent review listed the follow NUTM1 fusion gene-associated sarcomas: Colorectal sarcomas: Six cases, all with a MXD4-NUTM1 ... It is generally accepted that the BRD4-NUT protein promotes these neoplasms by maintaining their neoplastic cells in a ...
... cecal neoplasms MeSH C04.588.274.476.411.184.290 - appendiceal neoplasms MeSH C04.588.274.476.411.307 - colorectal neoplasms ... colorectal neoplasms, hereditary nonpolyposis MeSH C04.588.274.476.411.307.790 - rectal neoplasms MeSH C04.588.274.476.411.307. ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ...
... colorectal neoplasms MeSH C06.405.469.860.180.500 - rectal neoplasms MeSH C06.405.469.860.180.500.040 - anus neoplasms MeSH ... cecal neoplasms MeSH C06.301.371.411.184.290 - appendiceal neoplasms MeSH C06.301.371.411.307 - colorectal neoplasms MeSH ... cecal neoplasms MeSH C06.405.249.411.184.290 - appendiceal neoplasms MeSH C06.405.249.411.307 - colorectal neoplasms MeSH ... cecal neoplasms MeSH C06.405.469.491.184.290 - appendiceal neoplasms MeSH C06.405.469.491.307 - colorectal neoplasms MeSH ...
... colorectal neoplasms, hereditary nonpolyposis MeSH C18.452.284.280 - fanconi anemia MeSH C18.452.284.520 - Li-Fraumeni syndrome ...
... colorectal neoplasms, hereditary nonpolyposis MeSH C16.320.700.305 - dysplastic nevus syndrome MeSH C16.320.700.330 - exostoses ...
Breast Neoplasms, Colorectal Neoplasms, Lung Neoplasms, Malignancies Multiple, Metastatic Cancer, Pancreatic Cancer, Refractory ... Brain Neoplasm, Central Nervous System Neoplasm, High Grade Glioma: Gliosarcoma, Medulloblastomas, Oligodendroglioma, Acute T ...
... can refer to: Small intestine cancer Colorectal cancer This disambiguation page lists articles associated ... with the title Intestinal neoplasms. If an internal link led you here, you may wish to change the link to point directly to the ...
Paris classification of colorectal neoplasms In colonoscopy, colorectal polyps can be classified by NICE (Narrow-band imaging ... Untreated colorectal polyps can develop into colorectal cancer. Colorectal polyps are often classified by their behaviour (i.e ... Hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch syndrome) is a hereditary colorectal cancer syndrome. It ... Gross appearance of a colectomy specimen containing two colorectal polyps and one invasive colorectal carcinoma Micrograph of a ...
H7 Shigella Salmonella Campylobacter jejuni Hemorrhoids Neoplasm - such as colorectal cancer Angiodysplasia Bleeding from a ... Colorectal Disease. 14 (8): 1020-8. doi:10.1111/j.1463-1318.2011.02824.x. PMID 21910819. S2CID 26514078. Oakland, K; Chadwick, ...
Over 40 percent of all mucinous carcinomas are colorectal. When found within the skin, mucinous carcinoma is commonly a round, ... A mucinous neoplasm (also called colloid neoplasm) is an abnormal and excessive growth of tissue (neoplasia) with associated ... neoplasms, and cysts, All stub articles, Oncology stubs, Epidermal nevi, neoplasm, cyst stubs). ... A malignant mucinous neoplasm is called a mucinous carcinoma. For example, for ovarian mucinous tumors, approximately 75% are ...
1996). "Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice". Cancer Res. 56 (16): 3842-9. PMID 8706033 ... Mouse models of colorectal cancer and intestinal cancer are experimental systems in which mice are genetically manipulated, fed ... 2002). "Colorectal cancer in mice genetically deficient in the mucin Muc2". Science. 295 (5560): 1726-9. Bibcode:2002Sci... ... Today we know that the beta-catenin protein (part of the Wnt signaling pathway) is implicated in colorectal carcinogenesis and ...
... especially for large or ulcerative neoplasms. Recently, the ESD technique is applied to esophageal or colorectal neoplasms in ... The resected size and shape can be controlled, en bloc resection is possible even in a large neoplasm, and neoplasms with ... So this technique can be applied to the resection of complex neoplasms such as large neoplasms, ulcerative non-lifting ... For a reliable en bloc resection of GI neoplasms, a new method of ER called endoscopic submucosal dissection (ESD) has been ...
... a type of colorectal cancer (ICD-10 code: C20) Caldwell 20 or North America Nebula, an emission nebula in the constellation ... a mix of concrete that has a compressive strength of 20 newtons per square millimeter Malignant neoplasm of rectum, ...
B-cell neoplasm, breast carcinoma, Burkitt's lymphoma, colorectal adenocarcinoma, carcinoma, cutaneous T cell lymphoma, ...
Although most associated neoplasms are gastrointestinal adenocarcinomas (stomach, liver, colorectal and pancreas), malignancies ... It is likely that various cytokines and other growth factors produced by the neoplasm are responsible for the abrupt appearance ...
The most common malignant neoplasms (cancers) of the liver are metastases; those arising from colorectal cancer are among the ... Most hepatectomies are performed for the treatment of hepatic neoplasms, both benign or malign. Benign neoplasms include ... In the latter case, the patient was a 58-year-old woman diagnosed with colorectal cancer which had metastasized to the liver.[ ... Prior to surgery, cytotoxic agents such as oxaliplatin given systemically for colorectal metastasis, or chemoembolization for ...
... and sebaceous neoplasms. Increased risk of prostate cancer and breast cancer has also been associated with Lynch syndrome, ... Colorectal cancer with MSI-high pathology in a person who is younger than 60 years of age 4. Colorectal cancer diagnosed in a ... Person with colorectal cancer and two or more first- or second-degree relatives with colorectal cancer or Lynch syndrome ... Colorectal cancer diagnosed before age 50 2. Presence of synchronous or metachronous colorectal or other Lynch syndrome ...
Colorectal Neoplasms Follow-Up after Surgery and Prognosis ... Colorectal Neoplasms Follow-Up after Surgery and Prognosis. Jan ... Screening for Colorectal Neoplasms *Classification Systems *Treatment *Colorectal Neoplasms Treatment *Prognosis *Follow-Up ... Colorectal cancer. *Colorectal Cancer definition *Presentation *Risk Factors *Epidemiology *Colorectal cancer Risk Factors * ... Risk factors for colorectal Neoplasia *Prevention *References Rebecca A. Barnetson and Malcolm G. Dunlop. Colon Cancer Genetics ...
... Clin Gastroenterol Hepatol. 2007 Feb;5(2): ... Insulin resistance, the core mechanism of metabolic syndrome, has been associated with the development of colorectal neoplasm, ... Results: Of all those enrolled, 27.1% of men and 18.9% of women met the criteria of metabolic syndrome, and 9.8% had colorectal ... Our study aimed to determine whether metabolic syndrome is associated with the risk and clinical presentation of colorectal ...
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation ... 2Frisk-of-developing-colorectal-cancer-and-benign-colorectal-neoplasm-in-patients-with-chronic-constipation%2F&base_url=https% ... 2Frisk-of-developing-colorectal-cancer-and-benign-colorectal-neoplasm-in-patients-with-chronic-constipation%2F&user_agent=CCBot ... www.analysisgroup.com/Insights/publishing/risk-of-developing-colorectal-cancer-and-benign-colorectal-neoplasm-in-patients-with- ...
Colorectal cancer imaging: A challenge for radiologists Journal Articles * Colorectal cancer screening of high-risk individuals ... Radiology in screening for colorectal cancer. Journal Articles * Signature Celebration of Gastroenterology , Colorectal Cancer ...
Colorectal cancer starts in the colon or rectum. It may not cause symptoms at first. Screening tests can help find it early, ... ClinicalTrials.gov: Colonic Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Colorectal Neoplasms (National ... Second Cancers After Colorectal Cancer (American Cancer Society) Also in Spanish * Treating Colorectal Cancer (Colorectal ... Colorectal Cancer Screening (National Cancer Institute) Also in Spanish * Colorectal Cancer Screening Tests (National Library ...
Primary GI neoplasms in children are rare entities. In 1960, the incidence of GI malignancies arising from the bowel was ... Colorectal Carcinoma. Colorectal carcinoma is the most common colonic malignancy in children and occurs with an incidence of ... encoded search term (Pediatric Gastrointestinal Neoplasms) and Pediatric Gastrointestinal Neoplasms What to Read Next on ... Pediatric Gastrointestinal Neoplasms Updated: May 31, 2022 * Author: Nathaniel Koo, MD; Chief Editor: Max J Coppes, MD, PhD, ...
Endoscopic submucosal dissection for colorectal neoplasms: Risk factors for local recurren Endoscopic submucosal dissection for ... This study aimed to evaluate such risk factors after ESD for colorectal neoplasms. Methods:. This retrospective study included ... Endoscopic submucosal dissection (ESD) is an effective procedure for the en bloc resection of colorectal neoplasms. However, ... colorectal neoplasms: Risk factors for local recurrence and long-term surveillance. Okumura, Taishi; Hayashi, Takemasa; Kudo, ...
... and play little role in colorectal cancer causation in Chinese. ... Colorectal Neoplasms / diagnosis * Colorectal Neoplasms / ... APC I1307K and the E1317Q variants are not present in Chinese colorectal cancer patients Genet Med. 2004 Jul-Aug;6(4):237-8. ... Conclusion: These variants are rare in these Asian populations, and play little role in colorectal cancer causation in Chinese ... Purpose: The APC I1307K and E1317Q variants predispose to colorectal adenomas and carcinomas in Caucasians, but data are ...
Jin H, Leng Q, Li C (August 2012). "Dietary flavonoid for preventing colorectal neoplasms". Colorectal Cancer Group. The ... "Red Meat (Beef, Pork, Lamb): Increases Risk of Colorectal Cancer". aicr.org. Retrieved 24 April 2023. Park S, Bae J, Nam BH, ... There is strong evidence that processed meat and red meat intake increases risk of colorectal cancer. Aflatoxin B1, a frequent ... The Western pattern diet has been generally linked to increased risk for colorectal cancer. Meta-analyses have found that diet ...
Categories: Colorectal Neoplasms Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Colorectal Neoplasms/pathology, Humans, Hyperthermia, Induced, Leukopenia/etiology, Logistic Models, Middle Aged, Mitomycin/ ... Colorectal Neoplasms/pathology; Humans; Hyperthermia, Induced; Leukopenia/etiology; Logistic Models; Middle Aged; Mitomycin/ ... The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer : a comparative ... Peritoneal Neoplasms/mortality, Postoperative Complications, Young Adult. in Journal of Surgical Oncology. volume. 109. issue. ...
Colorectal Neoplasms. Perera T, Young MR, Zhang Z, Murphy G, Colburn NH, Lanza E, Hartman TJ, Cross AJ, Bobe G. 2015. ...
Colorectal Neoplasms +. 1793. Fecal Incontinence +. 1. Rectocele. 0. anal fistula +. 0. anus disease +. 153. ...
Colorectal Neoplasms. Inflammatory Bowel Diseases. Matched-Pair Analysis. To see the data from this visualization as text, ...
Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by. tissue biopsy). - Metastatic colorectal ... Neoplasm Metastasis. .map{width:100%;height:300px;margin-bottom:15px;} Name. Location. ... At least 2 but not more than 3 prior chemotherapy regimens for colorectal cancer. - Adequate hematologic, renal and hepatic ... fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal. cancer. - Radiographic documentation of ...
Colorectal Neoplasms. Li Q, Löhr CV, Dashwood RH. 2009. Activator protein 2alpha suppresses intestinal tumorigenesis in the Apc ... Colonic Neoplasms. Wang R, Löhr CV, Fischer K, W Dashwood M, Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR, ... Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer.. Cancer Lett. 381(2):341 ... Reciprocal regulation of BMF and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer.. Cancer Lett. 381(2):341 ...
Colorectal Neoplasms. .map{width:100%;height:300px;margin-bottom:15px;} Name. Location. ... colorectal cancer treated with two dose schedules of Ro 31-7453.. - Compare the safety and tolerability of these regimens in ... A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes D) Colorectal Carcinoma (CRC) ... A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes D) Colorectal Carcinoma (CRC) ...
Colorectal Neoplasms. *Lung Carcinoma, Small-Cell. *Urothelial Cancer. *Gastroesophageal Junction Cancer. *Advanced Solid ... Lymphedema Melanoma Merkel Cell Carcinoma Mesothelioma Multiple Myeloma Myelodysplastic Syndrome Myeloproliferative Neoplasms ... Colorectal Cancer Screening Genetic Counseling Lung Cancer Screening Prostate Cancer Screening Wellness Clinic ...
Colorectal Neoplasms. *General Surgery. Academic Appointments. * Clinical Assistant Professor, Surgery - General Surgery ... Colorectal Surgery in Patients with HIV and AIDS: Trends and Outcomes over a 10-Year Period in the USA. Journal of ... He joined Stanford in 2019 and is excited to build a Stanford colorectal surgery practice in the East Bay at Stanford Tri- ... John Gahagan, MD is a Clinical Assistant Professor of Surgery in the Section of Colorectal Surgery. He has training in advanced ...
Colorectal Neoplasms (Colorectal Cancer) 06/01/2011 - "The introduction of monoclonal antibodies into the treatment protocols ... Neoplasms (Cancer) 01/01/2015 - "Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs ... 01/01/1998 - "Subsequent adjuvant trials will examine newer regimens with activity in advanced colorectal cancer, as well as ... 07/01/2010 - "Anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC) treatment are only effective in patients ...
High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011, 60, 829-836. [Google Scholar ... recent evidence elucidates that patients with NASH are more sensitive to developing colorectal adenomas and advanced neoplasms ...
Colorectal Neoplasms (Colorectal Cancer) 01/01/1986 - "[The place and importance of oncofetal proteins and the hemocult test in ... Neoplasms (Cancer) 10/01/1996 - "A few previous studies have demonstrated the expression or mutations of oncogenes and anti- ... Pancreatic Neoplasms (Pancreatic Cancer) 11/01/1986 - "[Studies on a pancreatic oncofetal antigen (POA) in patients with ... oncogenes as well as that of oncofetal antigens in intraductal papillary-mucinous neoplasm of the pancreas. ". 01/01/1978 - " ...
... in spite of the higher incidence and death rate of colorectal cancer in blacks, no difference exists in the overall prevalence ... Prevalence of Advanced, Precancerous Colorectal Neoplasms in Black and White Populations: A Systematic Review and Meta-analysis ... "Prevalence of Advanced, Precancerous Colorectal Neoplasms in Black and White Populations: A Systematic Review and Meta-analysis ... most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal ...
... combining the NBI International Colorectal Endoscopic classification and criteria for differentiation of SSA/Ps in a stepwise ...
Flat and depressed colorectal neoplasms. Soetikno, R.M., Kahng, L.S., Ono, A., Fujii, T. Curr. Opin. Gastroenterol. (2003) [ ... Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. Soetikno, R.M., ... Nonpolypoid (flat and depressed) colorectal neoplasms. Soetikno, R., Friedland, S., Kaltenbach, T., Chayama, K., Tanaka, S. ...
Multiple colorectal neoplasms in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol. 2008 Jan. 6(1):115-9. [QxMD MEDLINE ...
Diseases/Pathways annotated by Medline MESH: Colorectal Neoplasms Document information provided by NCBI PubMed. Text Mining ... double knockout for AMPK α1/α2 subunits and human colorectal carcinoma cells (HCT 116) with AMPK α1/α2 shRNA mediated knockdown ...
... colorectal neoplasms, occult blood, diagnostic tests, sensitivity, specificity ... Colorectal cancer was identified at histopathological examination. Patients completed a questionnaire about their symptoms ... The positive predictive value, negative predictive value, sensitivity, and specificity of Hemoccult Sensa® for colorectal ... test in detecting colorectal cancer in the above-mentioned outpatients.Patients: Symptomatic outpatients without known ...
Dietary flavonoid for preventing colorectal neoplasms. Cochrane Database Syst. Rev., Vol. 8.. CrossRef ... Flavonoids present in fruit and vegetables can prevent colorectal neoplasm (Jin et al., 2012). ... The dietary pattern (consuming red or processed food) of western culture may increase the development of colo-rectal cancer ( ... Dietary patterns and risk of colorectal cancer: A systematic review of cohort studies (2000-2011). Asian Pac. J. Cancer Prev., ...
  • In addition, many evidence-based nutritional interventions exist that may reduce the risk of developing colorectal cancer in those at high risk. (naturalmedicinejournal.com)
  • The importance of AMPK expression for radiation responses was investigated using both MEFs (mouse embryo fibroblasts) double knockout for AMPK α1/α2 subunits and human colorectal carcinoma cells (HCT 116) with AMPK α1/α2 shRNA mediated knockdown. (ucsc.edu)
  • We studied the expression of HMGB1 and whether it is a prognostic factor in colorectal carcinoma. (medscimonit.com)
  • The study included 110 cases that were histopathologically diagnosed with colorectal carcinoma from the tissue samples acquired by surgical resection and biopsy in Antalya Education and Research Hospital between 2008 and 2012. (medscimonit.com)
  • Scholars@Duke publication: Adenoma-like adenocarcinoma: a subtype of colorectal carcinoma with good prognosis, deceptive appearance on biopsy and frequent KRAS mutation. (duke.edu)
  • Colorectal carcinoma , the commonest malignant tumour of the gastrointestinal tract , is rather uncommon in Nigeria , occurring often at a relatively early age. (bvsalud.org)
  • To report experience with colorectal carcinoma in the University of Port Harcourt Teaching Hospital (UPTH). (bvsalud.org)
  • Colorectal carcinoma is relatively uncommon in our environment . (bvsalud.org)
  • Noninvasive testing for colorectal cancer: a review. (health.am)
  • A series of video about NOSES in colorectal surgery has been made with the purpose of comprehensively understanding this technique in treatment of colorectal cancer. (springer.com)
  • CONCLUSIONS: The laparoscopic approach was as safe and effective as laparotomy in the treatment of colorectal cancer, and was associated with increased operative time, shorter hospital stay and less morbidity. (scielo.br)
  • Advanced precancerous polyps are the precursor lesions for most colorectal cancers, the third most common cancer and the second-leading cause of cancer death in the United States among all racial and ethnic groups. (sciencedaily.com)
  • Given that differences in colorectal cancers incidence and mortality are not due to biological factors, differences in access to or uptake of screening for the disease appears to account for the higher incidence and death rates in blacks. (sciencedaily.com)
  • The new study reviewed and analyzed data of more than 300,000 average risk for colorectal cancers in men and women as reported in studies published between 2010 and 2017. (sciencedaily.com)
  • Colorectal cancer (CRC) is among the most frequently diagnosed cancers. (biomedcentral.com)
  • 2 Overall risk of colon cancer is approximately 5% in the general population without family history, with 92% of colorectal cancers diagnosed after age 50. (naturalmedicinejournal.com)
  • These genetic disorders account for 1-2% and 3-5% of all colorectal cancers, respectively. (naturalmedicinejournal.com)
  • While the incidence of colorectal cancer cases directly attributable to these genetic syndromes is small, they are highly penetrant, with a lifetime risk of 100% and 80% of developing colorectal cancers in those with FAP and Lynch syndrome respectively. (naturalmedicinejournal.com)
  • Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, also raise the risk of colorectal cancers considerably. (naturalmedicinejournal.com)
  • While IBD-related colorectal cancers account for only 1-2% of all CRC cases, CRC accounts for 10-15% of deaths in patients with IBD. (naturalmedicinejournal.com)
  • 7 Up to 70% of colorectal cancers may be due to preventable habits involving diet and lifestyle. (naturalmedicinejournal.com)
  • Interestingly, a recent review of 248 published papers found that the only symptoms with positive predictive value (PPV) for colorectal cancers were bleeding and weight loss. (naturalmedicinejournal.com)
  • Colorectal cancers is one of the world's top causes of cancer. (bvsalud.org)
  • Statins have been associated with a significantly lower risk of breast (8), colorectal (9), and lymph cancers (10-12) in several observational studies (10,13). (cdc.gov)
  • This is true for areas in both the top and bottom quintiles (96% and 93% respectively) based on the percentage of colorectal cancers (CRC) diagnosed at a late stage. (cdc.gov)
  • Compare the objective disease rate of patients with recurrent or refractory metastatic colorectal cancer treated with two dose schedules of Ro 31-7453. (knowcancer.com)
  • The combination is currently indicated for the treatment of adults with metastatic colorectal cancer that has a BRAF V600E mutation. (medscape.com)
  • Perivascular heterogeneity in clinical samples, and associations with other tumor features and outcome, remain largely unknown.Here we report a novel method for digital quantitative analyses of vessel characteristics and PC, which was applied to two collections of human metastatic colorectal cancer (mCRC).Initial analyses identified marker-defined subsets of PC, including cells expressing PDGFR-β or α-SMA or both markers. (lu.se)
  • It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease). (bvsalud.org)
  • Adenomas are colorectal polyps (growths) that look abnormal under a microscope or are 1 centimeter or larger. (medlineplus.gov)
  • The APC I1307K and E1317Q variants predispose to colorectal adenomas and carcinomas in Caucasians, but data are lacking in Asians. (nih.gov)
  • Colorectal adenomas are intraepithelial neoplasms that characteristically display epithelial dysplasia. (anatomywarehouse.com)
  • In addition to genetic syndromes and IBD, established risk factors include age, personal history of adenomas, family history of colorectal cancer, diets high in fat and low in fruit/vegetables, obesity, sedentary lifestyle, smoking, and excessive alcohol intake. (naturalmedicinejournal.com)
  • Microsatellite instability in young patients with sporadic colorectal adenomas. (kbsmc.co.kr)
  • Having a personal or family history of colorectal cancer. (medlineplus.gov)
  • Insulin resistance, the core mechanism of metabolic syndrome, has been associated with the development of colorectal neoplasm, but the interrelation between metabolic syndrome and colon cancer is rarely addressed. (nih.gov)
  • The trial will evaluate whether a trivalent adenovirus-5 vaccine (TriAd5) along with the IL-15 superagonist nogapendekin alfa inbakicept (N803) can stave off the development of colorectal neoplasms. (medscape.com)
  • What are the symptoms of colorectal cancer? (medlineplus.gov)
  • Common symptoms of colorectal cancer include alterations in bowel habit, rectal bleeding, weight loss, abdominal pain, obstructive symptoms, and changes in the caliber/shape of stool (See Table I). The general nature and prevalence of benign abdominal complaints make recognizing which patients may have a malignancy very challenging. (naturalmedicinejournal.com)
  • Endoscopic submucosal dissection for colorectal neoplasms: Risk factors for local recurrence and long-term surveillance. (bvsalud.org)
  • Endoscopic submucosal dissection (ESD) is an effective procedure for the en bloc resection of colorectal neoplasms . (bvsalud.org)
  • Design We developed the Workgroup serrAted polypS and Polyposis (WASP) classification, combining the NBI International Colorectal Endoscopic classification and criteria for differentiation of SSA/Ps in a stepwise approach. (bmj.com)
  • In the present study, we aimed to examine the feasibility of PCM-CT for colorectal endoscopic submucosal dissection (ESD). (thieme-connect.com)
  • Patients who did not undergo full colonoscopy preoperatively should undergo colonoscopy within 3-6 months postoperatively to exclude other synchronous colorectal neoplasms and 1 year thereafter. (health.am)
  • Colorectal cancer s found after a complete colonoscopy. (health.am)
  • Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. (health.am)
  • A systematic review and meta-analysis has found that, in spite of the higher incidence and death rate of colorectal cancer in blacks, no difference exists in the overall prevalence of advanced, precancerous polyps between average-risk blacks and whites who underwent a screening colonoscopy. (sciencedaily.com)
  • The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. (thieme-connect.de)
  • There are several colorectal screening options for average-risk individuals, including colonoscopy every 10 years, flexible sigmoidoscopy every 5 years, double-contrast barium enema every 5 years, CT colonography every 5 years, and annual fecal occult blood testing. (medscape.com)
  • CT and magnetic resonance (MR) colonography (virtual colonoscopy) techniques are being developed for the imaging of colorectal polyps and cancer. (medscape.com)
  • There is an increased risk in patients with a positive family history of colorectal adenocarcinoma. (anatomywarehouse.com)
  • ASGE guidelines: colorectal cancer screening and surveillance. (health.am)
  • Lieberman D. Screening for colorectal cancer in average-risk populations. (health.am)
  • The role of CT colography in colorectal cancer screening. (health.am)
  • Colorectal cancer screening of high-risk individuals. (mcmaster.ca)
  • Radiology in screening for colorectal cancer. (mcmaster.ca)
  • What is screening for colorectal cancer and who needs it? (medlineplus.gov)
  • Because colorectal cancer may not cause symptoms at first, it's important to have screening tests for colorectal cancer . (medlineplus.gov)
  • If you have symptoms that could be caused by colorectal cancer or if your screening test results are abnormal, you may need to have more tests to find out if you have cancer. (medlineplus.gov)
  • Because of the higher incidence and mortality rates in blacks, the current recommendation of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer recommend colorectal cancer screening beginning at 45 years for average-risk blacks, while the American College of Physicians recommends starting at age 40, five to ten years earlier than for non-blacks. (sciencedaily.com)
  • Long-Term Mortality after Screening for Colorectal Cancer. (thieme-connect.de)
  • This can hopefully translate in clinical practice to the development of better risk stratification tool for identifying high-risk individuals for early colorectal cancer screening, and identifying areas needed for further research to curb this rising trend. (wjgnet.com)
  • Screening and early diagnosis have profound effects on the prognosis of individuals with colorectal cancer, and recognizing those at high risk may save lives through early detection. (naturalmedicinejournal.com)
  • Multi-Society Task Force for Development of Guidelines for Colorectal Polyp Screening, Surveillance and Management. (kbsmc.co.kr)
  • A Korean national survey for colorectal cancer screening and polyp diagnosis methods using web-based survey] Korean J Gastroenterol. (kbsmc.co.kr)
  • Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. (kbsmc.co.kr)
  • Socioeconomic status is a strong predictor of colorectal cancer screening (4). (cdc.gov)
  • Patients and methods PCM-CT was performed on 30 patients with early colorectal tumors from October 2019 to April 2020. (thieme-connect.com)
  • A Novel Gene Which Is Up-Regulated during Colon Epithelial Cell Differentiation and Down-Regulated in Colorectal Neoplasms," Laboratory Investigation: A Journal of Technical Methods and Pathology, Vol. 77, No. 1, 1997, pp. 85-92. (scirp.org)
  • In the United States, colorectal cancer (CRC) ranks second to lung cancer as a cause of cancer mortality and is the third most commonly occurring cancer in both men and women. (lww.com)
  • The study will assess the relationship between asbestos exposure and colorectal cancer by asbestos exposures levels, as well as, the incidence and mortality rates of lung cancer in relation to the exposure to welding fumes. (cdc.gov)
  • There was excess mortality and incidence of cancer in the study cohort including excess mesothelioma, lung, and colorectal cancer. (cdc.gov)
  • Alaska Native colorectal cancer (CRC) incidence and mortality rates are the highest of any ethnic/racial group in the United States. (cdc.gov)
  • Our study aimed to determine whether metabolic syndrome is associated with the risk and clinical presentation of colorectal neoplasia. (nih.gov)
  • Logistic regression modeling was used to elucidate the association between colorectal neoplasia and metabolic syndrome. (nih.gov)
  • The impact of metabolic syndrome on distribution and number of colorectal neoplasia was also assessed. (nih.gov)
  • Of all those enrolled, 27.1% of men and 18.9% of women met the criteria of metabolic syndrome, and 9.8% had colorectal neoplasia. (nih.gov)
  • Metabolic syndrome was associated with odds ratio (OR) of 1.35 (95% confidence interval [CI], 1.05-1.73) for colorectal neoplasia. (nih.gov)
  • The sigmoid colon was the most common site presented by neoplasia and rectosigmoidectomy was performed more by open colorectal resection (p = 0.042). (scielo.br)
  • This study evaluated whether the newer immunochemical FOBT (iFOBT) resulted in a lower false-positive rate and higher specificity for detecting advanced colorectal neoplasia than gFOBT in a population with elevated prevalence of H. pylori infection. (cdc.gov)
  • Research of Low-frequency Microsatellite Instability has been linked to Microsatellite Instability, High-frequency Microsatellite Instability, Malignant Neoplasms, Neoplasms, Colorectal Cancer. (novusbio.com)
  • Colorectal cancer with at least one measurable tumor. (medscape.com)
  • We retrospectively analyzed the first 30 consecutive patients who underwent PCM-CT among a total of 80 cases of ESD for early colorectal tumors at Jichi Medical University Hospital between October 2019 and April 2020. (thieme-connect.com)
  • Prevalence of Advanced, Precancerous Colorectal Neoplasms in Black and White Populations: A Systematic Review and Meta-analysis" will be published in the December 2018 issue of Gastroenterology . (sciencedaily.com)
  • Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. (wikigenes.org)
  • This retrospective study included 1344 patients with 1539 consecutive colorectal lesions who underwent ESD between September 2003 and December 2019. (bvsalud.org)
  • We sequenced the APC gene from codons 1261 to 1409 and found none of 147 Chinese, 20 Malay, and 11 Indian colorectal cancer patients in Singapore to carry the APC I1307K or E1317Q variants. (nih.gov)
  • Eight of 256 patients were found to have colorectal cancer. (dovepress.com)
  • All patients provided their consent before undergoing colorectal ESD using PCM-CT, and this study was approved by the ethics committee of the Jichi Medical University, Tochigi, Japan. (thieme-connect.com)
  • Studies in patients with advanced colorectal cancer harboring BRAF mutations have shown favorable responses to [this] combination," Goldberg said. (medscape.com)
  • 11 The presence of severe anemia in those patients presenting with rectal bleeding also increases the PPV for colorectal cancer in a primary care setting. (naturalmedicinejournal.com)
  • ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. (spg.pt)
  • Objective: to realize a systematic review about cognitive and psycho-social intervention strategies in patients with colorectal cancer in randomized clinical trials. (bvsalud.org)
  • Patients treated for colorectal cancer at the UPTH over a 19- year period (1987-2006) and had complete information, were studied. (bvsalud.org)
  • Consequently, this article focuses on the more common benign and malignant neoplasms of the GI tract in children, in addition to information gleaned from the relatively sparse literature. (medscape.com)
  • N. van Belzen, W. N. Dinjens, B. H. Eussen and F. T. Bosman, "Expression of Differentiation-Related Genes in Colorectal Cancer: Possible Implications for Prognosis," Histology and Histopathology, Vol. 13, No. 4, 1998, pp. 1233-1242. (scirp.org)
  • The leading causes of deaths in the Long Beach Naval shipyard included diseases of the circulatory and neoplasms. (cdc.gov)
  • The book introduced 10 different techniques of NOSES for colorectal neoplasms based on extensive high-quality surgical images. (springer.com)
  • BACKGROUND: Surgical resection is the mainstay of treatment for colorectal cancer with curative intent. (scielo.br)
  • Colonic neoplasms associated with chronic inflammation conditions such as ULCERATIVE COLITIS and CROHN DISEASE. (bvsalud.org)
  • 12 One study from the United Kingdom showed that concomitant signs and symptoms with rectal bleeding doubles the likelihood of a colorectal cancer diagnosis. (naturalmedicinejournal.com)
  • Results The median specimen major axis length, ESD time, ESD speed, and en bloc resection rate were 48 mm, 84 minutes, 20 mm 2 /min, and 100 % (30/30), respectively. (thieme-connect.com)
  • Advances in chemotherapy for colorectal cancer. (health.am)
  • BACKGROUND: Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC). (lu.se)
  • Having a genetic syndrome such as familial adenomatous polyposis (FAP) or Lynch syndrome (hereditary non-polyposis colorectal cancer). (medlineplus.gov)
  • Lynch syndrome carries a 15% to 80% lifetime risk for colorectal cancer. (medscape.com)
  • AIMS: A subset of colorectal carcinomas (CRCs) architecturally and cytologically resembles adenomatous change, making them difficult to diagnose on biopsy. (duke.edu)
  • These variants are rare in these Asian populations, and play little role in colorectal cancer causation in Chinese. (nih.gov)
  • The incidence of colorectal cancer is highest in Western populations. (naturalmedicinejournal.com)
  • In 2002, a new diagnostic strategy in symptomatic outpatients without known established colorectal cancer risk factors aged 40 years or older was implemented in Denmark. (dovepress.com)
  • Symptomatic outpatients without known established colorectal cancer risk factors and without visible rectal bleeding. (dovepress.com)
  • Hemoccult Sensa ® as the initial examination in symptomatic outpatients without known established colorectal cancer risk factors presenting without rectal bleeding has to be used with caution. (dovepress.com)
  • Genetic tests are now routinely ordered to determine risk for developing and appropriate management of hereditary breast and ovarian cancer, hereditary nonpolyposis colorectal cancer, and many other hereditary cancer syndromes-often without formal genetic assessment by a credentialed professional. (ons.org)
  • 11 However, there is greater PPV for colorectal cancer when rectal bleeding is accompanied by changes in bowel habits, or when unaccompanied by perianal symptoms. (naturalmedicinejournal.com)
  • This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. (bvsalud.org)
  • But certain genetic changes that raise your risk for colorectal cancer are inherited, meaning that you are born with them. (medlineplus.gov)
  • Besides genetics, other factors, including your lifestyle and the environment, can affect your risk of colorectal cancer. (medlineplus.gov)
  • your risk of getting colorectal cancer increases as you age. (medlineplus.gov)
  • Black people have an increased risk of colorectal cancer and death from colorectal cancer compared to other races. (medlineplus.gov)
  • This study aimed to evaluate such risk factors after ESD for colorectal neoplasms . (bvsalud.org)
  • There is strong evidence that processed meat and red meat intake increases risk of colorectal cancer. (wikipedia.org)
  • The Western pattern diet has been generally linked to increased risk for colorectal cancer. (wikipedia.org)
  • For these reasons iFOBT has better specificity and equal or better sensitivity than gFOBT for the detection of colorectal neoplasms ( 9 , 10 ). (cdc.gov)
  • Primary gastrointestinal (GI) neoplasms in children are rare. (medscape.com)

No images available that match "colorectal neoplasms"